



SYSTEMATIC REVIEW

**UPDATE** Nicotine products relative risk assessment: an updated systematic review and meta-analysis

[version 2; peer review: 1 approved, 1 approved with reservations]

Previously titled: Nicotine products relative risk assessment: a systematic review and meta-analysis

Rachel Murkett, Megyn Rugh, Belinda Ding

Biochromex Ltd., London, UK

**v2** **First published:** 12 Oct 2020, 9:1225  
<https://doi.org/10.12688/f1000research.26762.1>  
**Latest published:** 20 Sep 2022, 9:1225  
<https://doi.org/10.12688/f1000research.26762.2>

**Abstract**

**Background:** The nicotine products relative risk assessment estimates the relative risk of tobacco-related diseases due to use of 15 nicotine products. This update adds new data to the original analysis and creates separate categories for United States and rest of world varieties of smokeless tobacco, as well as bidi cigarettes.

**Methods:** The PubMed®, MEDLINE and Clinicaltrials.gov databases were searched systematically. The study lists were exported, screened at the title, abstract and full-text level according to pre-defined inclusion/exclusion criteria. The study quality was assessed, and risk of bias was accounted for in the screening criteria. The extracted data was synthesized into a toxin emissions/content analysis for 12 Group 1 carcinogens, used to estimate lifetime cancer risk, and epidemiological meta-analysis of over 40 tobacco-related diseases. The two analyses were integrated into a combined risk score for each nicotine product, weighted by the risk of bias due to missing data, and incorporated into the relative risk spectrum.

**Results:**

In this update, 70 new studies were added to the synthesis, making a total of 123 studies included. All combustible tobacco products score between 40 and 100, with bidis and smokeless (rest of world) also in this range. All other products have a combined risk score of 10 or less, including U.S. chewing tobacco, U.S. dipping tobacco, snus, heat-not-burn tobacco, electronic cigarettes, non-tobacco pouches and nicotine replacement therapy.

**Discussion:** Consistent with previous studies, we define a group of high-risk nicotine products, scoring between 40 and 100 on the spectrum, and reduced risk nicotine products, scoring less than 10. Limitations of this study include the potential for bias due to missing data, the heterogeneity of the data included in the relative risk hierarchy synthesis, and the assumed consumption levels.

**Open Peer Review**

**Approval Status**

	1	2
<b>version 2</b> (update) 20 Sep 2022		
<b>version 1</b> 12 Oct 2020	 view	 view

1. **David Nutt**, Imperial College London, London, UK
2. **Mohamadi Sarkar** , Altria Client Services LLC, Richmond, USA  
**Chastain Anderson**, Altria Client Services LLC, Richmond, USA  
**Thaddeus Hannel**, Altria Client Services LLC, Richmond, USA  
**Brendan Noggle**, Altria Client Services LLC, Richmond, USA

Any reports and responses or comments on the article can be found at the end of the article.

**Keywords**

Nicotine products, relative risk, risk assessment, tobacco, harm reduction, systematic review.



This article is included in the **Health Services** gateway.

**Corresponding author:** Rachel Murkett ([rachel.murkett@biochromex.com](mailto:rachel.murkett@biochromex.com))

**Author roles:** **Murkett R:** Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Software, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Rugh M:** Data Curation, Formal Analysis, Investigation; **Ding B:** Data Curation, Formal Analysis, Investigation

**Competing interests:** This work is funded by a grant from the Foundation for a Smoke-Free World, Inc., a US non-profit 501(c)(3) private foundation with the mission of improving global health by ending smoking in this generation. The Foundation has received charitable contributions from PMI Global Services Inc. (PMI) in each of 2018 and 2019 in the amount of US \$80 million.

**Grant information:** The research presented was produced with the help of a grant from the Foundation for a Smoke-Free World, Inc. (FSFW), an independent, US non-profit 501(c)(3) grantmaking organization with the purpose of improving global health by ending smoking in this generation. The contents, selection, and presentation of facts, as well as any opinions expressed herein, are the sole responsibility of the authors and under no circumstances should they be regarded as reflecting the positions of FSFW. FSFW accepts charitable gifts from PMI Global Services Inc. (PMI); under FSFW's Bylaws and Pledge Agreement with PMI, FSFW is independent from PMI and the tobacco industry. Further details can be found here: <https://www.smokefreeworld.org/our-vision/>. *The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

**Copyright:** © 2022 Murkett R *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Murkett R, Rugh M and Ding B. **Nicotine products relative risk assessment: an updated systematic review and meta-analysis [version 2; peer review: 1 approved, 1 approved with reservations]** F1000Research 2022, 9:1225 <https://doi.org/10.12688/f1000research.26762.2>

**First published:** 12 Oct 2020, 9:1225 <https://doi.org/10.12688/f1000research.26762.1>

**UPDATE Updates from Version 1**

An update of this study was initiated in November 2021 with the aim of bringing the literature search up to date and incorporating feedback received during the presentation of this work to the scientific community. A point raised several times was the lack of representation of tobacco products in low and middle income countries in their own category and the inappropriateness of placing these products in the same category as those manufactured and marketed in the United States. This issue has been rectified by limiting the dipping and chewing tobacco categories to products marketed in the United States and creating additional categories for smokeless tobacco from the rest of the world (except snus which already has its' own category) and bidi cigarettes. We have also made efforts to improve the presentation of the study based on feedback regarding the lack of study characteristics tables and other pieces of data required for complete comprehension and reproduction of this work. In addition, the grant information and competing interests statements have been updated. Full details can be found in the main paper and in the extended information. We continue to encourage and welcome all constructive feedback from the scientific community and appreciate the comments of all those who take the time to read, consider, critique and debate its methods and findings.

**Any further responses from the reviewers can be found at the end of the article**

**Introduction**

Tobacco smoking is known to cause over 8 million premature deaths every year worldwide<sup>1</sup>. Since the discovery of its severe toxicity in the 1960s, bringing an end to tobacco smoking has been a major priority for public health authorities<sup>2-4</sup>. The toxicity is attributed to tobacco combustion, which generates at least 250 known toxins and 69 known carcinogens<sup>1,2</sup>. Combustible tobacco consumption dates back thousands of years, and in that time several products have been developed including factory-made and roll-your-own cigarettes, bidis, cigarillos, cigars, western pipe tobacco and water pipe tobacco<sup>5</sup>. Consumers of these products are exposed to toxins with each inhalation, increasing their risk of potentially fatal health outcomes, such as lung cancer, oral cancer or cardiovascular disease<sup>6</sup>.

Beyond combustion, tobacco can also be consumed by placing small amounts in the oral or nasal cavities<sup>7</sup>. The tobacco mixes with saliva and releases chemicals which are ingested and can be associated with increased risk of oral and gastrointestinal cancers<sup>7</sup>. Different varieties of smokeless tobacco contain widely varying levels of toxins, with further divergence depending on how they are manufactured and stored<sup>8</sup>. Types of smokeless tobacco include United States (U.S.) varieties of chewing and dipping tobacco, Swedish snus, and Asian varieties, such as naswar, mishri or gutka<sup>7</sup>. Asian varieties of smokeless tobacco are often associated with higher levels of toxicity than modern U.S. and Swedish varieties, which have shown steadily decreasing levels of toxins as manufacturing and storage processes are optimized for reduced toxicity<sup>7</sup>.

Most users consume tobacco for the pleasurable effects associated with nicotine, which often makes cessation challenging<sup>9</sup>. To minimize the harms caused by traditional tobacco products

and help people to quit, new methods of nicotine delivery have been developed that eliminate most of the known toxins associated with tobacco smoking and smokeless tobacco use<sup>10</sup>. Nicotine replacement therapies, electronic cigarettes, heated tobacco products, non-tobacco nicotine pouches and low tobacco-specific nitrosamines (TSNA)-varieties of smokeless tobacco have been introduced to the market, giving consumers the choice of several alternatives to higher risk tobacco products. The development of these alternative products has paved the way for tobacco harm reduction, which focuses on reducing the harms associated with smoking by encouraging users to switch to nicotine products with reduced toxicity e.g., nicotine replacement therapy (NRT), snus or e-cigarettes<sup>11</sup>. Success has been reported for harm reduction strategies in other areas of public health, such as alcohol abuse, where measures such as low-alcohol beverages have been introduced to reduce the harms associated with alcohol consumption while allowing the consumer to continue enjoying the product<sup>12</sup>. For many smokers, having access to products that deliver nicotine without the high toxicity of traditional tobacco products can mean the difference between successfully quitting smoking or continuing indefinitely. Indeed, there is a large body of high-quality evidence in the scientific literature supporting the efficacy of nicotine replacement for helping smokers to successfully stop smoking, increasing the rate of cessation by 50 – 60% compared with no intervention<sup>13</sup>.

While there is universal consensus regarding the significant harms of combustible tobacco products, and despite the observed efficacy of nicotine replacement therapies, the subject of tobacco harm reduction remains contentious. Harm reduction proponents argue in favor of the reduced risk profiles of non-combustible nicotine products and their potential benefits for public health if they were widely adopted instead of combustible tobacco products<sup>11,14</sup>. While tobacco harm reduction antagonists argue that not enough is known about the newer nicotine products, that they could even be just as harmful as combustible tobacco, and that they may be gateways to smoking for people who do not currently consume any nicotine products at all<sup>4,15</sup>.

The objective of this relative risk assessment of nicotine products is to systematically gather and appraise the best available evidence from the scientific literature regarding the risks of cancer and non-cancer tobacco-related diseases in healthy current users of a single nicotine product, compared with never and non-users of any nicotine product, at average consumption levels. In the first iteration of this study published in 2020, a systematic review, literature appraisal and analysis protocol were developed, which generates a combined risk score for each nicotine product based on the lifetime cancer risk (LCR), modelled from toxin emissions/content data, and epidemiological evidence of disease risk in exposed groups<sup>16</sup>. In the 2020 study, the combined risk score was calculated for 13 categories of nicotine products: combustible cigarettes, cut tobacco, cigarillos, western pipe tobacco, water pipe tobacco, cigars, dipping tobacco, chewing tobacco, heat-not-burn devices, snus, electronic cigarettes, non-tobacco pouches and

NRT. This relative risk assessment builds on previous studies in the scientific literature including Nutt *et al.*, 2014, which used a multi-criteria decision analysis model to assess the relative harms of 12 nicotine products, Abrams *et al.*, 2018, which categorized the Nutt *et al.* spectrum into “extreme toxicity” and “much less harm” categories, and Stephens, 2018, which compared the lifetime cancer risk associated with vaporized nicotine products compared with tobacco smoke<sup>10,17,18</sup>. In this update, the systematic review and analysis developed in 2020 have been repeated, adding newly published data to fill some of the gaps and replace lower quality evidence with higher quality studies, where possible. We have also added minor methodological refinements where facilitated by new data. In addition, we have created two new product categories in the hierarchy, expanding the inclusion criteria of this study to incorporate smokeless tobacco from the rest of the world and bidis, a type of small hand-rolled cigarette/mini cigar originating from India.

## Methods

### Systematic literature review

This update follows the review and analysis protocol that were published previously, with a few minor amendments. Firstly, the systematic review was conducted according to the preferred reporting items for systematic review and meta-analysis

(PRISMA) 2020 checklist (rather than the 2009 version)<sup>19</sup>. Secondly, the original methodology covered 13 categories of nicotine products (chewing tobacco, combustible cigarettes, cigarillos, cigars, cut tobacco, dipping tobacco, electronic cigarettes, heat-not-burn devices, NRT, non-tobacco pouches, snus, water pipe tobacco and western pipe tobacco). This review adds two categories for bidis and smokeless products from the rest of the world, thereby expanding the selection criteria compared with the 2020 iteration, as well as focusing the dipping and chewing tobacco categories on U.S. varieties only. The full Population-Intervention-Comparison-Outcomes-Study type (PICOS) question addressed in this review is outlined in [Table 1](#).

Systematic searches were conducted using specific search terms pertaining to the health risks of nicotine products on May 9<sup>th</sup> 2022 in the MEDLINE ([Pubmed](#)) and NIH clinical trials ([ClinicalTrials.gov](#)) databases (see extended data). Due to the broad scope of the searches, the most relevant literature was targeted by searching at the title and abstract levels. The publication lists returned by the searches were exported and screened at the title, abstract and full-text levels according to pre-defined inclusion and exclusion criteria ([Table 2](#)). The screening steps were completed by one researcher and

**Table 1. The adapted Population-Intervention-Comparison-Outcomes-Study type (PICOS) question used to determine the inclusion criteria.**

<b>Population</b>	Healthy adults
<b>Intervention (Exposure group)</b>	Current average user of a single nicotine product
<b>Comparator</b>	Never and non-users of any nicotine product
<b>Outcome</b>	Incidence of cancer and non-cancer tobacco-related diseases
<b>Study type</b>	Epidemiological studies and toxin emissions/content studies

**Table 2. The inclusion and exclusion criteria applied to exported studies in the literature screening.**

Inclusion criteria	Exclusion criteria
Studies that report on the health risks to primary consumers of nicotine products	Studies that report only on the efficacy of nicotine products for smoking cessation
Studies that report on specific health risk metrics or information related to the use of a nicotine product	Studies that focus on ethical, environmental or sociological factors associated with the use of nicotine products
Studies reporting on epidemiological data of nicotine product health risks	Non-human studies
Studies reporting on toxin emissions and content of nicotine products*	Non-English studies
	<i>In vitro</i> studies
Removed inclusion/exclusion criteria	
Only U.S./western smokeless tobacco products	Asian smokeless tobacco products
Risks related to secondhand and thirdhand consumption	

\*Criteria not present in original study.

confirmed by a second. During each screening step, the reason for exclusion of each individual publication was recorded and the level of evidence assessed for the final shortlisted publications using the Oxford evidence-based medicine level of evidence scale<sup>20</sup>.

### Data extraction and harmonization

The shortlisted studies were analyzed in detail to extract health risk data and relevant meta-data, including the nicotine product, brand, disease/symptom, methodology used, measurement and unit, error in measurement, significance of measurement, geographic location, sample size and conflict of interest.

For the toxin emissions/content studies, only data points for Group 1 International Agency for Research on Cancer (IARC) carcinogens were extracted. Data were sought for NNN and NNK, formaldehyde, 2-amino-naphthalene, 4-aminobiphenyl, benzo(a)pyrene, 1,3-butadiene, benzene, vinyl chloride, ethylene oxide, arsenic, chromium-IV and cadmium for inhalable products, and NNN and NNK, benzo(a)pyrene, arsenic, chromium-IV and cadmium for ingestible products. In addition, studies that reported sample collection conducted before 1<sup>st</sup> January 1990 were excluded due to lack of relevance to the current market.

For the epidemiological studies, only adjusted odds ratios pertaining to tobacco-related diseases were extracted and only data points that adjusted for smoking were included. Data were sought for myocardial infarction, stroke, cardiovascular disease, coronary heart disease, atrial fibrillation, heart disease, asthma, asthma attack, bronchitis, wheeze, COPD, CHD mortality, cardiovascular disease mortality, chronic lower respiratory disease, cerebrovascular disease mortality and chronic obstructive pulmonary disease mortality for the non-cancer outcomes. Data were sought for oral cancer, oropharyngeal cancer, mouth cancer, lip cancer, tongue cancer, cancers of the upper aero-digestive tract, head and neck cancer, larynx cancer, esophageal cancer, hypopharyngeal cancer, lung cancer, pancreatic cancer, stomach cancer, bladder cancer, rectal cancer, gastrointestinal cancer, colorectal cancer, anal cancer, liver cancer, cardia cancer, kidney cancer, cervical cancer, non-Hodgkin's lymphoma, acute lymphoblastic lymphoma, acute myeloid lymphoma, chronic myeloid lymphoma multiple myeloma and cancer mortality for the cancer outcomes. Where stratification was available, data points for current users were prioritized over former/ever users, data points for both sexes were prioritized over single sex datasets (within the same study), and non- or never users of any other nicotine product were prioritized over dual users. If stratification was provided by consumption level, moderate consumption matching as closely as possible to the assumptions used in the LCR analysis were selected. In applying these additional selection criteria to the data, we aim to adjust for confounders, reduce the risk of bias and focus on risk associated with the same consumption levels across all analyses. No automation tools were used for data extraction and all data points were verified by a second reviewer. The information extracted included the nicotine

product, brand, disease/symptom, methodology used, measurement and unit, error in measurement, significance of measurement, geographic location, sample size and conflict of interest.

### Data analysis

The extracted and harmonized dataset was analyzed in two main segments: lifetime cancer risk and epidemiological data.

**Lifetime cancer risk.** The lifetime cancer risk (LCR) of each nicotine product was calculated separately for inhalable and smokeless products. The inhalable products LCR calculation was based on the methodology outlined by Stephens<sup>9</sup>, whereas the LCR of the smokeless products was determined using the methodology outlined by the FDA<sup>10</sup>.

The LCR of each inhalable nicotine product was calculated from the toxin emissions data by adjusting the OEHHA unit risk values<sup>12</sup>. A total of 12 toxins are included in the inhalable nicotine product analysis. The toxins selected are all International Agency for Research on Cancer (IARC) Group 1 carcinogens ("known carcinogens") for which OEHHA unit risk values and emissions data were available<sup>13</sup>. The protocol used in this study deviates slightly from that of Stephens. Firstly, whereas in Stephen's protocol Group 1 and Group 2B carcinogens are included, only Group 1 carcinogens were included here<sup>18</sup>. The Group 1 carcinogens were selected because this grouping applies to toxins for which "sufficient evidence" of cancer in humans has been observed, whereas in the Group 2B category only "limited" or "inadequate" evidence of cancer in humans is available, meaning that the classification in this group is primarily based on evidence from experimental animals or mechanistic studies<sup>21</sup>. In this review, we exclude evidence from animal or *in vitro* studies, therefore Group 2B carcinogens (as well as Group 2A and 3) were also excluded from this toxin emissions analysis. Secondly, we convert the unit risk values to risk per  $\mu\text{g}$  or  $\text{ng}$  per breath in order to match the units of the converted toxin concentrations, which are reported per puff. This is contrary to the methodology outlined by Stephens, which takes unit risk values in their original form of risk per  $\mu\text{g}$  per  $\text{m}^3$  and adjusts the smoke/vapour toxicants to match these units.

For each carcinogen, the OEHHA unit risk values were sourced and converted from risk per  $\mu\text{g}$  per  $\text{m}^3$  to risk per  $\mu\text{g}$  per breath by assuming the average breath volume of a healthy human is 500 mL<sup>14</sup>. The toxin emissions of the nicotine products were reported in varying units. For instance, combustible cigarette studies reported toxin emissions as  $\mu\text{g}$  or  $\text{ng}$  per stick, whereas electronic cigarette studies reported toxin emissions as  $\mu\text{g}$  or  $\text{ng}$  per 150 puffs. Therefore, the toxin emissions data for each product were converted to per puff values. In order to make this conversion, the average number of puffs per product per session was extracted from puff topography studies in the scientific literature (see extended data<sup>11</sup>). The cancer potency of each nicotine product was calculated by adjusting the unit risk values with the observed masses of toxins in the

emissions from each inhaled nicotine product using Equation 1:

$$P_i = \sum_{j=1}^m C_{i,j} U_j$$

*Equation 1: Cancer potency of the nicotine product*

Where  $P_i$  is the cancer potency of the  $i$ th nicotine product,  $C_{i,j}$  is the mass of the  $j$ th toxin in the  $i$ th nicotine product and  $U_j$  is the unit risk for the  $j$ th toxin. The cancer potency ( $P_i$ ) represents the excess cancer risk associated with continuous lifetime use of each nicotine product. To put the cancer potency values into real-world context, the lifetime cancer risk was calculated by adjusting the cancer potency values for average consumption patterns of each product, using Equation 2:

$$LCR_i = P_i \frac{D_i}{B}$$

*Equation 2: Lifetime cancer risk of inhalable nicotine products*

Where  $LCR_i$  is the lifetime cancer risk of the  $i$ th nicotine product,  $P_i$  is the cancer potency of the  $i$ th nicotine product,  $D_i$  is the average daily number of puffs taken by users of each nicotine product and  $B$  is the average number of breaths taken in one day (40,000 breaths, equivalent of 20 m<sup>3</sup> breathed per day). The lifetime cancer risk ( $LCR_i$ ) represents the excess cancer risk associated with average daily use of each nicotine product over the course of a person's lifetime.

For the non-inhaled (smokeless) products, the estimated lifetime cancer risk (ELCR) equation as defined by the FDA was used<sup>10</sup>. This equation calculates the lifetime cancer risk based on adjustment of the cancer slope factor for each carcinogen with the observed amounts of toxins measured in smokeless tobacco products and average consumption of the products:

$$ELCR_i = \sum_{j=1}^m C_{i,j} IR_j \frac{AB_j EF_j ED_j}{BWAT} CSF_j$$

*Equation 3: Estimated lifetime cancer risk of smokeless nicotine products*

Where  $ELCR_i$  is the estimated lifetime cancer risk of the  $i$ th product,  $C_{i,j}$  is the concentration of the  $j$ th toxin in the  $i$ th product,  $IR_{i,j}$  is the intake rate of the  $j$ th toxin in the  $i$ th product,  $AB_{i,j}$  is the absorption rate of the  $j$ th toxin in the  $i$ th product,  $EF_{i,j}$  is the exposure frequency of the  $j$ th toxin in the  $i$ th product,  $ED_{i,j}$  is the exposure duration of the  $j$ th toxin in the  $i$ th product,  $BW$  is the body weight of the average user,  $AT$  is the averaging time of use and  $CSF_j$  is the cancer slope factor of the  $j$ th toxin.

**Epidemiological data analysis.** Risk ratios, odds ratios and hazard ratios were extracted from the epidemiological studies and a set of meta-analyses were performed to determine the relative risk of cardiovascular disease, respiratory disease, cancer and mortality in users of each nicotine product compared to non-users of any nicotine products. The epidemiological data extracted from the systematic literature searches was screened to include only relative risk values that compared

current users of a single nicotine product to non-users of any nicotine product. Relative risk values were excluded if they were unadjusted for tobacco smoking. Where more than one study was available for a specific disease, the best available evidence was selected according to the Oxford Center for Evidence-based Medicine Level of Evidence Scale<sup>20</sup>. For instance, if a meta-analysis of prospective cohort studies and a single case-control study were available, the former would be included and the latter would be excluded.

The remaining data after screening were grouped by disease type into cardiovascular disease, respiratory disease, cancer and mortality. The cancer category was further broken out into oral, other head and neck, lung, gastrointestinal and other. Meta-analyses of the relative risk data for each disease category were conducted using a random-effects model in the **Comprehensive Meta-analysis (CMA) software Version 3.3**, with a statistical significance threshold of  $\alpha = 0.05$ . The meta-analysis could also be conducted in the open-access alternative, the **metaphor package** of R. A final meta-analysis was conducted to obtain overall relative risk ratios of cancer and non-cancer diseases for each nicotine product.

### Missing data

In the LCR analysis, several of the combustible products lacked data points for multiple toxins. As the LCR was calculated for each toxin and then summed for each product, missing data points significantly skewed the result towards lower risk. In order to compensate for this, the missing data points for combustibles were filled with values from combustible cigarettes, for which all data points were available. The assumption being that the mechanism of combustion is likely to produce a similar profile of toxins. This assumption was applied to 92% of the data points for bidis, 58% for cut tobacco, 50% of the data points for cigars, 50% for cigarillos and 33% for water pipe tobacco. The room for error due to this assumption should be noted, particularly for bidis where almost all of the data points are assumed from combustible cigarettes.

In the epidemiological data analysis, no data were available for the cut tobacco category and very few studies differentiated between factory-made and roll-your-own cigarette smokers. Therefore, it was assumed that the studies investigating cigarette smokers most likely included a mix of factory-made and roll-your-own, with both identifying as combustible cigarette smokers. Based on this assumption, as well as the assumption that the two products would carry comparable risk, we used the same data for the combustible cigarettes and cut tobacco categories. No other assumptions were made in the epidemiological analysis and missing data was simply recorded using the data completeness score.

For each product, a data completeness score was derived which shows to what extent data points were available for each product and category of data. It serves to give an indication of the risk of error due to missing data for each product. The data completeness is calculated as a percentage, where all

the possible data points for each product represent 100% and any missing data is calculated as a fraction of this total as follows.

$$DC_i = \frac{n_{a,i}}{n_{t,i}} \times 100$$

*Equation 1: Data completeness for each nicotine product*

Where  $DC_i$  is data completeness for the  $i$ th nicotine product,  $n_{a,i}$  is the number of data points available for the  $i$ th nicotine product and  $n_{t,i}$  is the total number of possible data points for the  $i$ th nicotine product. The higher the data completeness percentage, the lower the risk of bias due to missing data.

### Relative risk hierarchy

The RRH combines the results of the lifetime cancer risk and epidemiological analysis, with a weighting system that accounts for the completeness of the dataset. In order to integrate these two analyses into a combined risk score for each nicotine product, an arbitrary scale from 0 to 100 was defined, with 0 representing non-users of nicotine products and 100 representing users of combustible cigarettes. Combustible cigarettes were selected as the top of the scale because they were the highest risk product in both of the analyses. Non-user groups were the control or baseline in both analyses, therefore no correction was required to the lower end of the scale. After converting both analyses onto a 100-point scale, a weighting of 68 was applied to the lifetime cancer risk analysis and 54 to the epidemiological analysis, according to the data completeness scores for each component.

### Sensitivity analysis

The sensitivity of the RRH to each analysis was determined by simulating several weightings of the lifetime cancer risk and epidemiological data and assessing their outcomes on the risk hierarchy (see extended data). The analyses were weighted 68:54, 1:1 and 54:68, producing three simulations of the RRH.

### Statistical software

Data was extracted from the scientific literature into a Microsoft Excel Version 16.41 spreadsheet. Microsoft Excel was used to conduct the lifetime cancer risk calculations. **Comprehensive Meta-analysis (CMA) software Version 3.3** was used to conduct statistical meta-analyses in the epidemiological data-analysis. Calculation of the combined risk scores that were incorporated into the RRH was completed in Microsoft Excel.

## Results

### Search results

A PRISMA flow diagram of the updated literature searches is shown in [Figure 1](#). In this update, a total of 23,781 studies were identified in the literature searches. Of these, 5,981 were excluded as duplicates. At the title screening step, 14,876 studies were excluded, primarily due to lack of relevance to the PICOS question. This left 2,907 publications that were assessed in greater detail at the abstract level, where 2,027 studies were excluded. This left 880 studies to be examined at the full-text review, where 810 studies were excluded and 70 were included

from the latest round of searches. This made a total of 123 unique studies included in the analysis.


### Study characteristics

The 70 new studies consist of 40 new toxin emissions studies and 30 new epidemiological studies. The new epidemiological studies consist of 12 meta-analyses, 10 single cohort studies, five case-control studies, two cross-sectional studies and one randomized controlled trial ([Table 3](#)). The sample sizes for cohort and cross-sectional studies are over 1,000, over 100 for case-control studies (combined case and controls) and they range from 33 to 75 for different groups in the randomized controlled trial. In total, 14 studies include only male participants, the rest are mixed with only one study limited to an exclusively female population. The confounder adjustment varies across the studies mostly because the risk for different diseases, populations and products are affected by different confounders. All included odds ratios are adjusted for smoking and the majority are also adjusted for other common risk factors, such as age, sex and socio-economic factors. Only two studies on NRT and snus have a declared conflict of interest. For the former, one of the three study authors is an employee of a consulting company that has provided services to GlaxoSmithKline consumer healthcare (a marketer of NRT products) and the other study is jointly funded by Philip Morris Products, Swedish Match and the European Smokeless Tobacco Council.

There are 40 new toxin emissions studies included in this update ([Table 4](#)). The new data covers combustible cigarettes, cigars, U.S. dipping tobacco, e-cigarettes, heated tobacco products, snus, cut tobacco, smokeless (rest of world), non-tobacco nicotine pouches and NRT. The protocols used to determine toxin emissions are mostly well described and the majority comply with a published standard (e.g., international standards organization or Health Canada Intense). Most studies use the HCI condition with a puff volume of 55 mL, puff duration of 2 or 3 seconds and puff interval of 30 seconds. For cigars and cut tobacco, a puff volume of 35 mL is used. The EN ISO 17294-2:2016/EN 13805:2014 was used for non-tobacco pouches, NRT and one of the snus studies. The remaining studies used in-house methods or protocols referenced elsewhere in the scientific literature. Of the 41 studies, 10 were funded by and/or conducted by researchers at tobacco companies and five studies had another declared conflict of interest.

### Lifetime cancer risk analysis

Toxin emissions/content data were available for all the product categories excluding western pipe tobacco, which was therefore excluded from the LCR analysis. The calculated cancer potency, assumed consumption, LCR, and number of excess cancer cases per 100,000 are presented in [Table 5](#), as well as the data completeness score. The data completeness, including the combustible product assumption, is 100% for all products except the nicotine inhalator, which only has 25% of the data points. For bidis, over 90% of the data is assumed from combustible cigarettes meaning that the actual LCR may be



**Figure 1. Preferred Reporting Items for Updated Systematic Review and Meta-Analysis (PRISMA) flow diagram.**

prone to shift if more data becomes available. This is also true to a lesser extent for cut tobacco, cigarillos, cigars and water pipe tobacco.

The LCR data for each product is also plotted as a value relative to NRT in [Figure 2](#). Combustible cigarettes have a relative LCR of 655.3, bidis of 652.2, cut tobacco of 645.5, cigarillos of 547.3, cigars of 330.1 and water pipe tobacco of 325.5, compared to NRT. There was not a significant amount of new data in the combustible categories so the associated LCRs have not shifted significantly compared with the 2020 iteration of this study. Bidis enter the scale just below combustible cigarettes, although it is important to note that the data

available for bidis was very limited so this position may be subject to change. The smokeless (rest of world) category enters the scale at 223.3, with very large error bars representing the wide range of toxicity of products in this category. For example, the study by Zakiullah et al investigates the toxin content of 30 brands of Pakistani naswar and reports that the cadmium concentration ranges from below the detection limit (<0.01) to 9.2 mg/kg, whereas for other product categories the ranges were generally smaller, such as NRT with a cadmium concentration of 0.01 – 0.029 µg/g.

The heat-not-burn and electronic cigarette products have relative LCRs of 29.7 and 22.3, respectively. U.S. dipping tobacco,

**Table 3. Study Characteristics of new epidemiological studies included in this update.** The new epidemiological studies are listed here by product then disease. Descriptive details of the location, study design and sample size are provided. The odds ratio with the 95% confidence intervals in brackets are listed with the confounders adjusted for in the odds ratio. Declared conflicts of interest are also shown.

Disease	Reference	Location	Design	Sample size	Gender	Odds ratio (95% CI)	Confounders adjusted	Conflict of interest
COMBUSTIBLE CIGARETTES								
Hypopharyngeal cancer	Jayalekshmi <i>et al.</i> , 2013 <sup>24</sup>	India	Prospective cohort study	27,835	Men	1.6 (0.9 – 2.8)	Age, family income	None declared
Liver cancer	Hassan <i>et al.</i> , 2008 <sup>23</sup>	USA	Case-control study	206 (488)	Men and women	1.5 (1.1 – 2.2)	Age, sex, race, education, marital status, state of residency, HCV, HBV, diabetes, heavy alcohol consumption and family history of cancer.	None declared
Cardiac cancer	Ye <i>et al.</i> , 1999 <sup>24</sup>	Sweden	Case-control study	13 (64)	Men and women	2.2 (1 – 4.8)	Age, residence area, BMI, socio-economic status, use of smokeless tobacco, and use of beer, wine and liquor	None declared
Acute lymphoblastic leukemia	Fernberg <i>et al.</i> , 2007 <sup>25</sup>	Sweden	Prospective cohort study	98,183	Men	1.94 (0.89 – 4.21)	Age, BMI, non-users of snuff	None declared
Acute myeloid lymphoma						1.29 (0.89 – 1.86)		
U.S. CHEWING TOBACCO								
Stroke	Gupta <i>et al.</i> , 2020 <sup>26</sup>	USA	Meta-analysis (cohort & case-control studies)	7 studies	Men and women	1.21 (0.9 – 1.51)	Smoking	None declared
Coronary heart disease	Gupta <i>et al.</i> , 2019 <sup>27</sup>	USA	Meta-analysis (cohort studies)	2 studies	Men and women	1.04 (0.83 – 1.24)	Never users of other tobacco products	None declared
Liver cancer	Hassan <i>et al.</i> , 2008 <sup>23</sup>	USA	Case-control study	103 (540)	Men and women	0.3 (0.02 – 3.9)	Smoking, age, sex, race, education, marital status, state of residency, HCV, HBV, diabetes, heavy alcohol consumption, and family history of cancer.	None declared
Cancer mortality	Henley <i>et al.</i> , 2005 <sup>28</sup>	USA	Prospective cohort study	114,809	Men	1.23 (1.02 – 1.49)	Never users of other tobacco products, Race, education, current alcohol consumption, exercise, aspirin use, body mass index, quartiles of vegetable and fruit consumption, dietary fat consumption and type of occupation	None declared
U.S. DIPPING TOBACCO								
Coronary heart disease	Gupta <i>et al.</i> , 2019 <sup>27</sup>	USA	Meta-analysis (cohort & case-control studies)	7 studies	Men and women	0.96 (0.86 – 1.06)	Non-smokers only	None declared
Liver cancer	Hassan <i>et al.</i> , 2008 <sup>23</sup>	USA	Case-control study	102 (517)	Men and women	0.4 (0.03 – 5.1)	Cigarette smoking, age, sex, race, education, marital status, state of residency, HCV, HBV, diabetes, heavy alcohol consumption and family history of cancer.	None declared

Disease	Reference	Location	Design	Sample size	Gender	Odds ratio (95% CI)	Confounders adjusted	Conflict of interest
Cancer mortality	Henley <i>et al.</i> , 2005 <sup>28</sup>	USA	Prospective cohort study	114,809	Men	1.23 (1.02 – 1.49)	Never users of other tobacco products; race, education, current alcohol consumption, exercise, aspirin use, body mass index, quartiles of vegetable and fruit consumption, dietary fat consumption and type of occupation	None declared
All-cause mortality						1.17 (1.11 – 1.23)		
CHD mortality						1.12 (1.03 – 1.21)		
CVD mortality						1.18 (1.11 – 1.26)		
ELECTRONIC CIGARETTES								
Bronchitis	Braymiller <i>et al.</i> , 2020 <sup>29</sup>	USA	Cross-sectional	2,196	Men and women	0.96 (0.63 – 1.46)	*Nicotine vapers only	None declared
Wheeze						0.85 (0.54 – 1.35)	Cannabis vaping, sex, age, race/ethnicity, personal financial status, BMI, frequency of combustible cigarette use and frequency of combustible cannabis use	
SNUS								
Coronary heart disease	Hansson <i>et al.</i> , 2009 <sup>30</sup>	Sweden	Prospective cohort study	16,642	Men	0.85 (0.51 – 1.41)	Never smokers only, age, BP, diabetes, cholesterol	None declared
Atrial fibrillation	Hergens <i>et al.</i> , 2014 <sup>31</sup>	Sweden	Meta-analysis (cohort)	7 studies	Men	0.97 (0.71 – 1.33)	Never smokers only, age, BMI, education	None declared
Heart disease	Lee, 2011 <sup>32</sup>	Sweden	Meta-analysis (cohort and case-control studies)	9 studies	Men and women	0.99 (0.85 – 1.14)	Never-smokers only (all), age, area of residence	Study funded by Philip Morris Products, Swedish Match and the European Smokeless Tobacco Council
Oropharyngeal cancer/pharyngeal					Men and women	1.01 (0.71 – 1.45)	Never smokers only, age, alcohol intake	
Lung cancer					Men and women	0.82 (0.52 – 1.28)	Never-smokers only, age	
Stomach cancer					Men and women	0.90 (0.35 – 2.30)	Never-smokers only, age	
Oral cancer	Araghi <i>et al.</i> , 2021 <sup>33</sup>	Sweden	Meta-analysis (cohort)	9 studies	Men	0.79 (0.63 – 1.00)	Smoking, attained age and BMI	None declared
Bladder cancer	Boffetta <i>et al.</i> , 2005 <sup>34</sup>	Norway	Prospective cohort study	10,136	Men	0.72 (0.52 – 1.06)	Smoking of cigarettes, cigars and pipe, age	None declared
Kidney cancer						0.47 (0.23 – 0.94)		
Pancreatic cancer	Araghi <i>et al.</i> , 2017 <sup>35</sup>	Sweden	Meta-analysis (cohort)	9 studies	Men	0.96 (0.83 – 1.11)	Smoking, attained age and BMI	None declared
Rectal cancer	Nordenvall <i>et al.</i> , 2011 <sup>36</sup>	Sweden	Retrospective cohort study	336,381	Men	1.05 (0.85 – 1.31)	Non-smokers only, age, "other risk factors"	None declared
Anal cancer						0.61 (0.07 – 5.07)		
Cardia cancer	Ye <i>et al.</i> , 1999 <sup>4</sup>	Sweden	Case-control study	9 (118)	Men and women	0.5 (0.2 – 1.1)	Age, residence area, BMI, socio-economic status, use of smokeless tobacco, and use of beer, wine and liquor	None declared

Disease	Reference	Location	Design	Sample size	Gender	Odds ratio (95% CI)	Confounders adjusted	Conflict of interest
Acute lymphoblastic leukemia	Fernberg <i>et al.</i> , 2007 <sup>25</sup>	Sweden	Prospective cohort study	40,932	Men	1.24 (0.39 – 4.01)	Non-smokers; age, BMI	None declared
Acute myeloid lymphoma						0.81 (0.41 – 1.6)		
Chronic myeloid leukemia						1.17 (0.6 – 2.28)		
Multiple myeloma						0.92 (0.61 – 1.4)		
All-cause mortality	Byhamre <i>et al.</i> , 2021 <sup>37</sup>	Sweden	Meta-analysis (cohort)	169,103	Men	1.28 (1.20 – 1.35)	Never-smokers; attained age, BMI	None declared
Cardiovascular disease mortality						1.27 (1.15 – 1.41)		
Cancer mortality						1.12 (1.00 – 1.26)		
WESTERN PIPE TOBACCO								
All-cancer	Malhotra <i>et al.</i> , 2017 <sup>28</sup>	Global	Meta-analysis (cohort)	21,930	Men and women	1.19 (0.82 – 1.73)	*Ever users Age, gender, BMI, race/ethnicity, socioeconomic status, alcohol intake, family history of cancer	None declared
Acute lymphoblastic leukemia	Fernberg <i>et al.</i> , 2007 <sup>25</sup>	Sweden	Prospective cohort study	16,988	Men	0.84 (0.18 – 3.92)	"Pure pipe smoker", Age, BMI	None declared
Acute myeloid lymphoma						1.38 (0.85 – 2.24)		
WATER PIPE TOBACCO								
Heart disease	Islami <i>et al.</i> , 2013 <sup>39</sup>	Global	Meta-analysis (cohort)	21,930	Men and women	1.83 (1.1 – 3.07)	*Ever users Age, gender, BMI, race/ethnicity, socioeconomic status, alcohol intake, family history of cancer	None declared
SMOKELESS (REST OF WORLD)								
Myocardial infarction (paan)	Alexander, 2013	Pakistan	Case-control study	578 (757)	Men and women	1.53 (1.14 – 2.05)	Non-smokers; age, sex, ethnicity, LDL-C, waist-to-hip ratio, history of diabetes or hypertension and family history of MI	None declared
Stroke (Nass)	Etemadi <i>et al.</i> , 2017 <sup>40</sup>	Northeastern Iran	Meta-analysis (cohort & case-control studies)	1,393	Men and women	0.98 (0.65 – 1.47)	Smoking	None declared
Heart Disease (Mishri)	Gupta <i>et al.</i> , 2005 <sup>41</sup>	India	Cohort	97,244	Men	0.89 (0.75 – 1.05)	Smoking, age education	None declared
Bronchitis	Yusuf <i>et al.</i> , 2008 <sup>42</sup>	South Africa	Cross-sectional	4,425	Women	1.18 (0.69 – 2.03)	Smoking, Age, Socioeconomic status, tuberculosis, cooking fuel, occupational exposure to irritants	None declared

Disease	Reference	Location	Design	Sample size	Gender	Odds ratio (95% CI)	Confounders adjusted	Conflict of interest
Oral cancer (Paan/Betel quid with tobacco)	Asthana <i>et al.</i> , 2019 <sup>43</sup>	India	Meta-analysis (cohort & case-control studies)	4 studies	Men and women	7.43 (6.54 – 8.43)	Smoking	None declared
Mouth cancer (Pan-tobacco)	Sankaranarayanan <i>et al.</i> , 1989 <sup>44</sup>	India	Case-control study	87 (181)	Men	4.06 (1.95 – 8.4)	Smoking, alcohol and snuff use	None declared
Larynx cancer (Khaini, Zarda, Mawa, Pan, Gutkha)	Sapkota <i>et al.</i> , 2007 <sup>45</sup>	India	Meta-analysis (case-control studies)	5 studies	Men and women	1.112 (0.651 – 1.898)	Never smokers only, center, age, sex, SES, alcohol consumption, tobacco snuffing, tobacco pack years	None declared
Hypopharyngeal cancer (Khaini, Zarda, Mawa, Pan, Gutkha)						3.102 (2.03 – 4.741)		
BIDS								
Myocardial infarction	Teo <i>et al.</i> , 2006 <sup>46</sup>	Global	Case-control study	12,461 (14,637)	Men and women	2.89 (2.11 – 3.96)	Smoking bidis only, age, gender	None declared
Cardiovascular disease	Duong <i>et al.</i> , 2017 <sup>47</sup>	India & Pakistan	Prospective cohort study	9,479	Men	1.55 (1.17 – 2.06)	*Sample contains users of both cigarettes and bidis (26%), as well as exclusive bidi smokers (74%)	None declared
COPD, chronic bronchitis, emphysema or asthma						1.73 (1.23 – 2.45)	Socioeconomic status, age, BMI, asset index, education, cooking fuel, INTERHEART risk score, diabetes, hypertension and center	
Oral cancer	Jayalekshmi <i>et al.</i> , 2010 <sup>48</sup>	India	Prospective cohort study	66,277	Men and women	1.1 (0.7 – 1.5)	Tobacco use, attained age, calendar time, income, education, alcohol drinking	None declared
Mouth cancer	Sankaranarayanan <i>et al.</i> , 1989 <sup>44</sup>	India	Case-control study	49 (140)	Men	2.12 (1.19 – 27.88)	Smoking, alcohol and snuff use	None declared
Larynx cancer	Jayalekshmi <i>et al.</i> , 2013 <sup>42</sup>	India	Prospective cohort study	25,403	Men	4.4 (1.8 – 10.8)	Never smokers, attained age, family income	None declared
Hypopharyngeal cancer						3.1 (1.0 – 9.4)		
Lung cancer	Jayalekshmy <i>et al.</i> , 2008 <sup>49</sup>	India	Prospective cohort study	7,562	Men	4.9 (2.4 – 10)	Never smokers, attained age, religion, education, family income, occupation	None declared
Stomach cancer	Jayalekshmi <i>et al.</i> , 2015 <sup>50</sup>	India	Prospective cohort study	25,403	Men	1.9 (1.1 – 3.4)	Tobacco use, alcohol use, calendar year, attained age, occupation, education	None declared
NICOTINE REPLACEMENT THERAPY								
Lung cancer	Murray <i>et al.</i> , 2009 <sup>51</sup>	USA	Randomized controlled trial	75	Men and women	1.04 (0.97 – 1.12)	Cigarettes per day, lifetime pack-years of smoking, age, and sex	Third author is employed by Pinney Associates, which provides services to GSK consumer healthcare
Gastrointestinal cancer						0.97 (0.82 – 1.14)		
All-cancer						1.01 (0.97 – 1.06)		

**Table 4. Study Characteristics of new toxin emissions studies included in this update.** The new toxin emissions studies included in the lifetime cancer risk analysis are listed by product then toxin. The concentrations are reported in their original units, as extracted from the studies and before conversion for the analysis. Details of the products tested, protocol and parameters are listed (where available), as well as any declared conflict of interest. NS stands for "Not stated".

Toxin	Reference	Product	Concentration	Protocol	Parameters	Conflict of interest
COMBUSTIBLE CIGARETTES						
NNN and NNK	Murphy <i>et al.</i> , 2018 <sup>32</sup>	3R4F	49.91 ng/puff	HCl Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	Study by researchers at British American Tobacco
Formaldehyde	Tayyarah and Long, 2014 <sup>33</sup>	Marlboro Gold, L&B	7.12 – 10.4 µg/puff	CAN method	Puff volume 55 mL, puff duration NS, puff interval 30 s	Study by researchers at Lorillard Tobacco Company
1,3-butadiene	Murphy <i>et al.</i> , 2018 <sup>32</sup>	3R4F	9.91 µg/puff	HCl Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	Study by researchers at British American Tobacco
Benzene	Tayyarah and Long, 2014 <sup>33</sup>	Marlboro Gold, L&B	9.63 – 10.3 µg/puff	CAN method	Puff volume 55 mL, puff duration NS, puff interval 30 s	Study by researchers at Lorillard Tobacco Company
Benzo(a)pyrene	Murphy <i>et al.</i> , 2018 <sup>32</sup>	3R4F	1.18 ng/puff	HCl Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	Study by researchers at British American Tobacco
Cadmium	Tayyarah and Long, 2014 <sup>33</sup>	Marlboro Gold, L&B	1.33 – 2.07 ng/puff	CAN method	Puff volume 55 mL, puff duration NS, puff interval 30 s	Study by researchers at Lorillard Tobacco Company
CIGARS						
Benzene	Appel <i>et al.</i> , 1990 <sup>34</sup>	Cigar (brand not disclosed)	228 – 1025 µg/stick	FTC standard	Puff volume 35 mL, puff duration 2 s, puff interval 30 s	None declared
Benzo(a)pyrene	Appel <i>et al.</i> , 1990 <sup>34</sup>	Cigar (brand not disclosed)	96 – 292 ng/stick	FTC standard	Puff volume 35 mL, puff duration 2 s, puff interval 30 s	None declared
U.S. DIPPING TOBACCO						
NNN and NNK	Song <i>et al.</i> , 2016 <sup>35</sup>	Husky Straight Long-cut, Grizzly Fine Cut Wintergreen Fine cut, Timber Wolf Fine Cut Natural Fine cut, Copenhagen Mid-Cut Black Bourbon Flavored, Copenhagen Pouches, Copenhagen Snuff, Skoal Bandits Mint	6.02 µg/g DWB	Not stated (chemical analysis performed externally)	N/A	None declared
	Richter <i>et al.</i> , 2008 <sup>35</sup>	40 brands of top-selling moist snuff in United States in 2004	8.694 ng/g	Richter and Spierto, 2003 method	N/A	None declared
	Stepanov <i>et al.</i> , 2006 <sup>37</sup>	Ariva Hard snuff	56 ng/g WWB	Modified version of previously published method Adams <i>et al.</i> , 1983 method	N/A	None declared
Benzo(a)pyrene	Song <i>et al.</i> , 2016 <sup>35</sup>	Husky Straight Long-cut, Grizzly Fine Cut Wintergreen Fine cut, Timber Wolf Fine Cut Natural Fine cut, Copenhagen Mid-Cut Black Bourbon Flavored, Copenhagen Pouches, Copenhagen Snuff, Skoal Bandits Mint	77.75 ng/g DWB	Not stated (chemical analysis performed externally)	N/A	None declared

Toxin	Reference	Product	Concentration	Protocol	Parameters	Conflict of interest	
ELECTRONIC CIGARETTES	Murphy <i>et al.</i> , 2018 <sup>34</sup> Margham <i>et al.</i> , 2016 <sup>35</sup> Tayyarah and Long, 2014 <sup>33</sup> Belushkin <i>et al.</i> , 2020 <sup>39</sup> Laugesen, 2008 <sup>30</sup> Li <i>et al.</i> , 2021 <sup>61</sup> Farsalinos <i>et al.</i> , 2017 <sup>32</sup> Salamanca <i>et al.</i> , 2018 <sup>33</sup> Murphy <i>et al.</i> , 2018 <sup>32</sup> Nicol <i>et al.</i> , 2020 <sup>34</sup> Tayyarah and Long, 2014 <sup>33</sup> Geiss <i>et al.</i> , 2015 <sup>65</sup> Son <i>et al.</i> , 2020 <sup>65</sup> Chen <i>et al.</i> , 2021 <sup>67</sup> Belushkin <i>et al.</i> , 2020 <sup>39</sup> Landmesser <i>et al.</i> , 2021 <sup>68</sup> Nyakutsikwa <i>et al.</i> , 2021 <sup>69</sup> Farsalinos <i>et al.</i> , 2018 <sup>70</sup>	Vype ePen and eCaps Vype ePen SKYCIG and blue eCig 34 e-cigarette devices Ruyan (16 mg cartridge) 3 <sup>rd</sup> generation Evolv DNA 75 Color modular vaping device CE4 top coil atomizer, Innokin iTaste W V3.0 variable voltage battery device and Halo Café Mocha liquid with 6 mg/mL nicotine concentration CE4 top coil atomizer with Innokin iTaste W V3.0 variable voltage battery Vype ePen and eCaps "Conventional e-cigarette" SKYCIG and blue eCig Second generation refillable e-cigarettes Cig-a-like, Top-coil, mod', JUUL Vapros Spinner II vape pen 34 e-cigarette devices Not described Not described Nautilus mini atomizer and Evic VTC Mini variable wattage battery	0.006 ng/puff < 1.245 (LOD) – 3.28 ng/15 puffs < 0.06 ng/puff < 0.083 – 0.173 ng/puff 5.33 ng/cartridge 0.15 µg/puff 71.82 µg/puff 13.5 µg/puff (at 7.3 V) 0.398 µg/puff 5.48–5.5 µg/100 puffs < 0.35 µg/puff 19–23.5 ng/puff 0.04 – 1.35 ng/puff 126 – 22,717 ng/puff 484 – 31,400 ng/puff 22.6 – 39.1 ng/puff 0.16 µg/L 0.5 – 1 µg/12 puffs	HCl Condition HCl Condition CAN method CORESTA CRM No. 81 "Labstat method TWT-333" CORESTA protocol Not stated Not stated HCl Condition HCl Condition CAN method ISO 3308 Not stated Not stated CORESTA CRM No. 81 CORESTA CRM No. 81 Not stated HCl Condition	Puff volume 55 mL, puff duration 3 s, puff interval 30 s Puff volume 55 mL, puff duration 3 s, puff interval 30 s Puff volume 55 mL, puff duration NS, puff interval 30 s Puff volume 55/80 mL, puff duration 3/4 s, puff interval 30 s Puff volume 60 mL, puff duration NS, puff interval NS Puff volume 55 mL, puff duration 3 s, puff interval NS Puff volume 60 mL, puff duration 4 s, puff interval 30 s Puff volume 60 mL, puff duration 4 s, puff interval 30 s Puff volume 55 mL, puff duration 3 s, puff interval 30 s Puff volume 55 mL, puff duration 3 s, puff interval 30 s Puff volume 55 mL, puff duration NS, puff interval 30 s Puff volume 35 mL, puff duration 4 s, puff interval 30 s Puff volume 25 mL, puff duration 3 s, puff interval 30 s Puff volume NS, puff duration 4 s, puff interval 25 s Puff volume 55/80 mL, puff duration 3/4 s, puff interval 30 s Puff volume 55 mL, puff duration 4 s, puff interval 25 s Puff volume NS, puff duration NS, puff interval NS Puff volume 55 mL, puff duration 2 s, puff interval 30 s	Study by researchers at British American Tobacco Study by researchers at British American Tobacco Study by researchers at Lorillard Tobacco Company Study by researchers at PMI R&D Study funded by Ruyan® e-cigarettes One author has received consulting fees from ENDS manufacturers One author has received consulting fees from ENDS manufacturers None declared Study by researchers at British American Tobacco Study by researchers at British American Tobacco Study by researchers at Lorillard Tobacco Company None declared None declared None declared Study by researchers at PMI R&D Two authors employed by Altria Client Services, LLC One author is a member of WHO and ISO working groups One author received funding from AEMSA and Tennessee Smoke-Free Association	
							Formaldehyde

Toxin	Reference	Product	Concentration	Protocol	Parameters	Conflict of interest
1,3-butadiene	Murphy <i>et al.</i> , 2018 <sup>52</sup>	Vype ePen and eCaps	0.001 µg/puff	HCI Condition	Puff volume 55 mL, puff duration 3 s, puff interval 30 s	Study by researchers at British American Tobacco
	Tayyarah and Long, 2014 <sup>53</sup>	SKYCIG and blue eCig	< 0.0005 µg/puff	CAN method	Puff volume 55 mL, puff duration NS, puff interval 30 s	Study by researchers at Lorillard Tobacco Company
Benzene	Murphy <i>et al.</i> , 2018 <sup>52</sup>	Vype ePen and eCaps	0.001 µg/puff	HCI Condition	Puff volume 55 mL, puff duration 3 s, puff interval 30 s	Study by researchers at British American Tobacco
	Tayyarah and Long, 2014 <sup>53</sup>	SKYCIG and blue eCig	< 0.0005 µg/puff	CAN method	Puff volume 55 mL, puff duration NS, puff interval 30 s	Study by researchers at Lorillard Tobacco Company
	Lee <i>et al.</i> , 2017 <sup>71</sup>	Cigalike	0.5 – 6.6 ppb	Not stated	Puff volume NS, puff duration NS, puff interval 30 s	None declared
Benz[a]pyrene	Tayyarah and Long, 2014 <sup>53</sup>	SKYCIG and blue eCig	< 0.02 ng/puff	CAN method	Puff volume 55 mL, puff duration NS, puff interval 30 s	Study by researchers at Lorillard Tobacco Company
	Murphy <i>et al.</i> , 2018 <sup>52</sup>	Vype ePen and eCaps	0.006 ng/puff	HCI Condition	Puff volume 55 mL, puff duration 3 s, puff interval 30 s	Study by researchers at British American Tobacco
4-aminobiphenyl	Marqham <i>et al.</i> , 2016 <sup>58</sup>	Vype ePen	< 0.05 µLOQ ng/15 puffs	HCI Condition	Puff volume 55 mL, puff duration 3 s, puff interval 30 s	Study by researchers at British American Tobacco
	Nicol <i>et al.</i> , 2020 <sup>54</sup>	“Conventional e-cigarette”	< 0.014 µg/100 puffs	HCI Condition	Puff volume 55 mL, puff duration 3 s, puff interval 30 s	Study by researchers at British American Tobacco
	Tayyarah and Long, 2014 <sup>53</sup>	SKYCIG and blue eCig	< 0.01 ng/puff	CAN method	Puff volume 55 mL, puff duration NS, puff interval 30 s	Study by researchers at Lorillard Tobacco Company
2-naphthylamine	Marqham <i>et al.</i> , 2016 <sup>58</sup>	Vype ePen	< 0.12 (LOQ) ng/15 puffs	HCI Condition	Puff volume 55 mL, puff duration 3 s, puff interval 30 s	Study by researchers at British American Tobacco
	Marqham <i>et al.</i> , 2016 <sup>58</sup>	Vype ePen	< 6.57 (LOD) ng/15 puffs	HCI Condition	Puff volume 55 mL, puff duration 3 s, puff interval 30 s	Study by researchers at British American Tobacco
Ethylene oxide	Marqham <i>et al.</i> , 2016 <sup>58</sup>	Vype ePen	< 0.36 (LOD) µg/15 puffs	HCI Condition	Puff volume 55 mL, puff duration 3 s, puff interval 30 s	Study by researchers at British American Tobacco
Cadmium	Marqham <i>et al.</i> , 2016 <sup>58</sup>	Vype ePen	< 16.4 (LOD) – 22 ng/15 puffs	HCI Condition	Puff volume 55 mL, puff duration 3 s, puff interval 30 s	Study by researchers at British American Tobacco
	Tayyarah and Long, 2014 <sup>53</sup>	blue eCig	< 4 ng/puff	CAN method	Puff volume 55 mL, puff duration NS, puff interval 30 s	Study by researchers at Lorillard Tobacco Company
	Belushkin <i>et al.</i> , 2020 <sup>59</sup>	34 e-cigarette devices	< 0.06 ng/puff	CORESTA CRM No. 81	Puff volume 55/80 mL, puff duration 3/4 s, puff interval 30 s	Study by researchers at PMI R&D
Arsenic	Tayyarah and Long, 2014 <sup>53</sup>	blue eCig	< 4 ng/puff	CAN method	Puff volume 55 mL, puff duration NS, puff interval 30 s	Study by researchers at Lorillard Tobacco Company
	Belushkin <i>et al.</i> , 2020 <sup>59</sup>	34 e-cigarette devices	< 0.12 – 1.33 ng/puff	CORESTA CRM No. 81	Puff volume 55/80 mL, puff duration 3/4 s, puff interval 30 s	Study by researchers at PMI R&D
	Nyakutsikwa <i>et al.</i> , 2021 <sup>69</sup>	Not described	0.004 µg/L	Not stated	Puff volume NS, puff duration NS, puff interval NS	One author is a member of WHO and ISO working groups

Toxin	Reference	Product	Concentration	Protocol	Parameters	Conflict of interest
Chromium	Margham <i>et al.</i> , 2016 <sup>58</sup>	Vype ePen	10.5 ng/15 puffs	HCI Condition	Puff volume 55 mL, puff duration 3 s, puff interval 30 s	Study by researchers at British American Tobacco
	Tayyarah and Long, 2014 <sup>33</sup>	SKYCIG and blue eCig	0.01 – 0.09 ng/puff	CAN method	Puff volume 55 mL, puff duration NS, puff interval 30 s	Study by researchers at Lorillard Tobacco Company
	Nyakutsikwa <i>et al.</i> , 2021 <sup>69</sup>	Not described	0.007 µg/L	Not stated	Puff volume NS, puff duration NS, puff interval NS	One author is a member of WHO and ISO working groups
	Belushkin <i>et al.</i> , 2020 <sup>39</sup>	34 e-cigarette devices	< 0.09 – 1.8 ng/puff	CORESTA CRM No. 81	Puff volume 55/80 mL, puff duration 3/4 s, puff interval 30 s	Study by researchers at PMI R&D
HEATED TOBACCO PRODUCTS						
NNN and NNK	Murphy <i>et al.</i> , 2018 <sup>52</sup>	THP1.0, THS2.2 and H-THP	0.006 – 3.975 ng/puff	HCI Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	Study by researchers at British American Tobacco
	Schaller <i>et al.</i> , 2016 <sup>72</sup>	THS2.2 FR1 and THS2.2 FR1 M	19.6 - 23.9 ng/stick	HCI Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	Study by researchers at PMI
	Li <i>et al.</i> , 2019 <sup>73</sup>	THS 2.2	17.8 ng/stick	HCI Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	None declared
	Forster <i>et al.</i> , 2018 <sup>74</sup>	THP1.0(T) and THP1.0(M)	< 0.029 µg/consumable	HCI Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	Study by researchers at BAT
Formaldehyde	Murphy <i>et al.</i> , 2018 <sup>52</sup>	THP1.0, THS2.2 and H-THP	0.04 – 0.494 µg/puff	HCI Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	Study by researchers at British American Tobacco
	Mallock <i>et al.</i> , 2018 <sup>75</sup>	2 tobacco heating devices (brands not named)	4.7 – 5.3 µg/stick	HCI Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	None declared
	Salman <i>et al.</i> , 2019 <sup>6</sup>	IQOS	0.85 µg/stick	HCI Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	One author is a paid consultant in litigation against tobacco industry
	Schaller <i>et al.</i> , 2016 <sup>72</sup>	THS2.2 FR1 and THS2.2 FR1 M	4.55 – 5.53 µg/stick	HCI Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	Study by researchers at PMI
	Li <i>et al.</i> , 2019 <sup>73</sup>	THS 2.2	21.87 µg/stick	HCI Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	None declared
	Farsalinos <i>et al.</i> , 2018 <sup>70</sup>	IQOS	5 – 6.4 µg/stick	HCI Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	One author received funding from AEMSA and Tennessee Smoke-Free Association
	Forster <i>et al.</i> , 2018 <sup>74</sup>	THP1.0(T) and THP1.0(M)	< 3.29 – 3.51 µg/consumable	HCI Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	Study by researchers at BAT
	Kim <i>et al.</i> , 2020 <sup>77</sup>	Three brands of HTP	0.539 – 0.64 µg/stick	HCI Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	None declared

Toxin	Reference	Product	Concentration	Protocol	Parameters	Conflict of interest
1,3-butadiene	Murphy <i>et al.</i> , 2018 <sup>22</sup>	THP1.0, THS2.2 and H-THP	0.001 – 0.019 µg/puff	HCI Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	Study by researchers at British American Tobacco
	Mallock <i>et al.</i> , 2018 <sup>5</sup>	2 tobacco heating devices	0.2 – 0.22 µg/stick	HCI Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	None declared
	Schaller <i>et al.</i> , 2016 <sup>2</sup>	THS2.2 FR1 and THS2.2 FR1 M	0.265 – 0.294 µg/stick	HCI Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	Study by researchers at PMI
	Li <i>et al.</i> , 2019 <sup>3</sup>	THS 2.2	0.45 µg/stick	HCI Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	None declared
Benzene	Forster <i>et al.</i> , 2018 <sup>4</sup>	THP1.0(T) and THP1.0(M)	< 0.029 µg/consumable	HCI Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	Study by researchers at BAT
	Murphy <i>et al.</i> , 2018 <sup>22</sup>	THP1.0, THS2.2 and H-THP	0.001 – 0.038 µg/puff	HCI Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	Study by researchers at British American Tobacco
	Mallock <i>et al.</i> , 2018 <sup>5</sup>	2 tobacco heating devices	0.54 – 0.63 µg/stick	HCI Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	None declared
	Schaller <i>et al.</i> , 2016 <sup>2</sup>	THS2.2 FR1 and THS2.2 FR1 M	0.640 – 0.649 µg/stick	HCI Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	Study by researchers at PMI
Benzo(a)pyrene	Li <i>et al.</i> , 2019 <sup>3</sup>	THS 2.2	0.61 µg/stick	HCI Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	None declared
	Forster <i>et al.</i> , 2018 <sup>4</sup>	THP1.0(T) and THP1.0(M)	< 0.056 µg/consumable	HCI Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	Study by researchers at BAT
	Murphy <i>et al.</i> , 2018 <sup>22</sup>	THP1.0, THS2.2 and H-THP	0.003 – 0.049 ng/puff	HCI Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	Study by researchers at British American Tobacco
	Schaller <i>et al.</i> , 2016 <sup>2</sup>	THS2.2 FR1 and THS2.2 FR1 M	< 1 – 1.29 ng/stick	HCI Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	Study by researchers at PMI
4-aminobiphenyl	Forster <i>et al.</i> , 2018 <sup>4</sup>	THP1.0(T) and THP1.0(M)	< 0.354 – 0.356 ng/consumable	HCI Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	Study by researchers at BAT
	Schaller <i>et al.</i> , 2016 <sup>2</sup>	THS2.2 FR1 and THS2.2 FR1 M	< 0.051 ng/stick	HCI Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	Study by researchers at PMI
	Forster <i>et al.</i> , 2018 <sup>4</sup>	THP1.0(T) and THP1.0(M)	< 0.005 ng/consumable	HCI Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	Study by researchers at BAT
	Schaller <i>et al.</i> , 2016 <sup>2</sup>	THS2.2 FR1 and THS2.2 FR1 M	< 0.035 – 0.046 ng/stick	HCI Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	Study by researchers at PMI
Arsenic	Forster <i>et al.</i> , 2018 <sup>4</sup>	THP1.0(T) and THP1.0(M)	< 0.004 – 0.012 ng/consumable	HCI Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	Study by researchers at BAT
	Schaller <i>et al.</i> , 2016 <sup>2</sup>	THS2.2 FR1 and THS2.2 FR1 M	< 1.13 ng/stick	HCI Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	Study by researchers at PMI
	Forster <i>et al.</i> , 2018 <sup>4</sup>	THP1.0(T) and THP1.0(M)	< 0.576 ng/consumable	HCI Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	Study by researchers at BAT
	Schaller <i>et al.</i> , 2016 <sup>2</sup>	THS2.2 FR1 and THS2.2 FR1 M	< 0.576 ng/consumable	HCI Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	Study by researchers at BAT

Toxin	Reference	Product	Concentration	Protocol	Parameters	Conflict of interest
Cadmium	Schaller <i>et al.</i> , 2016 <sup>2</sup>	THS2.2 FR1 and THS2.2 FR1 M	< 0.35 ng/stick	HCl Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	Study by researchers at PMI
	Forster <i>et al.</i> , 2018 <sup>4</sup>	THP1.0(T) and THP1.0(M)	< 0.162 ng/consumable	HCl Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	Study by researchers at BAT
Chromium	Schaller <i>et al.</i> , 2016 <sup>2</sup>	THS2.2 FR1 and THS2.2 FR1 M	< 0.55 ng/stick	HCl Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	Study by researchers at PMI
	Forster <i>et al.</i> , 2018 <sup>4</sup>	THP1.0(T) and THP1.0(M)	4.06 – 4.34 ng/consumable	HCl Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	Study by researchers at BAT
Ethylene oxide	Schaller <i>et al.</i> , 2016 <sup>2</sup>	THS2.2 FR1 and THS2.2 FR1 M	0.201 – 0.202 µg/stick	HCl Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	Study by researchers at PMI
Vinyl chloride	Schaller <i>et al.</i> , 2016 <sup>2</sup>	THS2.2 FR1 and THS2.2 FR1 M	< 3.54 ng/stick	HCl Condition	Puff volume 55 mL, puff duration 2 s, puff interval 30 s	Study by researchers at PMI
SNUJS						
NNN and NNK	Song <i>et al.</i> , 2016 <sup>5</sup>	Camel Frost Snus, Camel Spice Snus, Camel Original Snus, Marlboro Mild Snus, Marlboro Mint Snus, Marlboro Rich Snus, and Marlboro Spice Snus, Ettan Lossnus, General Mini Portion, and Skruf Stark Portion, Taxi Super Snuff Gwayi and Peter Stuyvesant Coffee Snus	1.44 µg/g DWB	Not stated (chemical analysis performed externally)	N/A	None declared
	Stepanov <i>et al.</i> , 2015 <sup>7</sup>	Swedish snus	0.393 – 0.441 µg/g WWB	In-house method	N/A	None declared
Arsenic	Song <i>et al.</i> , 2016 <sup>5</sup>	Camel Frost Snus, Camel Spice Snus, Camel Original Snus, Marlboro Mild Snus, Marlboro Mint Snus, Marlboro Rich Snus, and Marlboro Spice Snus, Ettan Lossnus, General Mini Portion, and Skruf Stark Portion, Taxi Super Snuff Gwayi and Peter Stuyvesant Coffee Snus	0.73 µg/g DWB	Not stated (chemical analysis performed externally)	N/A	None declared
Chromium	Azzopardi <i>et al.</i> , 2021 <sup>18</sup>	Granit Ice Blue White, Skruf Slim Fresh XStrong Mint, G3 Slim White XStrong Blue Mint	815 – 1,700 ng/g DWB	EN ISO 17294-2:2016/EN 13805:2014	N/A	Study by researchers at British American Tobacco
CUT TOBACCO						
Benz(a)pyrene	Appel <i>et al.</i> , 1990 <sup>54</sup>	Cut tobacco (brand not disclosed)	37 – 43 ng/stick	FTC standard	Puff volume 35 mL, puff duration 2 s, puff interval 30 s	None declared
BIDIS						
NNN and NNK	Wu <i>et al.</i> , 2004 <sup>59</sup>	14 bidi cigarette brands	10.69 – 88.2 ng/stick	FTC standard	Puff volume 35 mL, puff duration 2 s, puff interval 30 s	None declared

Toxin	Reference	Product	Concentration	Protocol	Parameters	Conflict of interest
SMOKELESS (REST OF WORLD)						
NNN and NIK	Stepanov <i>et al.</i> , 2006 <sup>57</sup>	Indian smokeless tobacco	0.13 – 105.3 µg/g	In-house method	N/A	None declared
	Idris <i>et al.</i> , 1991 <sup>86</sup>	Toombak	1.12 – 10.95 mg/g	In-house method	N/A	None declared
	Stepanov <i>et al.</i> , 2015 <sup>81</sup>	Chaini khiani	25.5 µg/g	In-house method	N/A	None declared
	Nasrin <i>et al.</i> , 2020 <sup>82</sup>	34 brands of zarda, gul and sada pata	1.2 – 67 µg/g	CORESTA (modified)	N/A	None declared
	Al-Mukhaini <i>et al.</i> , 2016 <sup>83</sup>	Afzal	2.22 µg/g	Lawler <i>et al.</i> , 2013 method (modified)	N/A	None declared
Benzo(a)pyrene	Stepanov <i>et al.</i> , 2017 <sup>84</sup>	Pandharpuri Sandeep, Om Special Pandharpuri, Tambakhu Gai Chhap, Miraj Tobacco, Chaini Khaini, Mawa '120-300', Mawa 'Bhola', Betel Quid/Banarasi Paan	0.078 - 41.51 µg/g	In-house method	N/A	None declared
	Orisakwe <i>et al.</i> , 2015 <sup>85</sup>	30 samples of Nigerian smokeless tobacco	9.88 µg/kg	Not stated	N/A	None declared
	Al-Rmalli <i>et al.</i> , 2011 <sup>86</sup>	Betel quid	4.56 mg/kg	In-house method	N/A	None declared
	Brima, 2016 <sup>87</sup>	33 samples of shamma	0.7 – 1 µg/g	In-house method	N/A	None declared
	Zakiullah <i>et al.</i> , 2012 <sup>88</sup>	30 Pakistani brands of naswar	0.15 – 14.04 mg/kg	In-house method	N/A	None declared
Cadmium	Hossain <i>et al.</i> , 2018 <sup>89</sup>	Zarda, gul	1.05 – 3.53 µg/g	In-house method	N/A	None declared
	Orisakwe <i>et al.</i> , 2014 <sup>90</sup>	30 Nigerian smokeless tobacco types	0.01 – 0.17 µg/g	In-house method	N/A	None declared
	Prabhakar <i>et al.</i> , 2013 <sup>91</sup>	DS Madras snuff, Shambhu, Minar, Madhu, Cool Lip, Hans, Parag 9000, Chaini Khaini, Bombay, Rajanigandha	1.43 µg/g	In-house method	N/A	None declared
	Brima, 2016 <sup>87</sup>	33 samples of shamma	0 - 0.03 µg/g	In-house method	N/A	None declared
	Guezquez <i>et al.</i> , 2021 <sup>92</sup>	Neffa	1.3 – 2.8 µg/g	In-house method	N/A	None declared
Chromium	Zakiullah <i>et al.</i> , 2012 <sup>88</sup>	30 Pakistani brands of naswar	BDL - 9.2 mg/kg	In-house method	N/A	None declared
	Hossain <i>et al.</i> , 2018 <sup>89</sup>	Zarda, gul	1.23 – 7.29 µg/g	In-house method	N/A	None declared
	Orisakwe <i>et al.</i> , 2014 <sup>90</sup>	30 Nigerian smokeless tobacco types	2.77 – 11.40 µg/g	In-house method	N/A	None declared
	Brima, 2016 <sup>87</sup>	33 samples of shamma	2.1 – 5.4 µg/g	In-house method	N/A	None declared
	Zakiullah <i>et al.</i> , 2012 <sup>88</sup>	30 Pakistani brands of naswar	0.8 – 54.05 mg/kg	In-house method	N/A	None declared

Toxin	Reference	Product	Concentration	Protocol	Parameters	Conflict of interest
NON-TOBACCO NICOTINE POUCHES						
NNN and NNK	Azzopardi <i>et al.</i> , 2021 <sup>78</sup>	Lyft freeze, lyft lime strong, lyft berry frost, lyft mint	< 20 ng/g	EN ISO 17294-2:2016/EN 13805:2014	N/A	Study by researchers at British American Tobacco
Benzo(a)pyrene	Azzopardi <i>et al.</i> , 2021 <sup>78</sup>	Lyft freeze, lyft lime strong, lyft berry frost, lyft mint	< 1 ng/g	EN ISO 17294-2:2016/EN 13805:2014	N/A	Study by researchers at British American Tobacco
Arsenic	Azzopardi <i>et al.</i> , 2021 <sup>78</sup>	Lyft freeze, lyft lime strong, lyft berry frost, lyft mint	< 50 – 80 ng/g	EN ISO 17294-2:2016/EN 13805:2014	N/A	Study by researchers at British American Tobacco
Chromium	Azzopardi <i>et al.</i> , 2021 <sup>78</sup>	Lyft freeze, lyft lime strong, lyft berry frost, lyft mint	< 50 ng/g	EN ISO 17294-2:2016/EN 13805:2014	N/A	Study by researchers at British American Tobacco
NICOTINE REPLACEMENT THERAPY						
NNN and NNK	Azzopardi <i>et al.</i> , 2021 <sup>78</sup>	NRT lozenge, 4 mg NRT gum, 4 mg	< 20 ng/g < 20 ng/g	EN ISO 17294-2:2016/EN 13805:2014	N/A	Study by researchers at British American Tobacco
Benzo(a)pyrene	Azzopardi <i>et al.</i> , 2021 <sup>78</sup>	NRT lozenge, 4 mg NRT gum, 4 mg	< 1 ng/g < 1 ng/g	EN ISO 17294-2:2016/EN 13805:2014	N/A	Study by researchers at British American Tobacco
Arsenic	Azzopardi <i>et al.</i> , 2021 <sup>78</sup>	NRT lozenge, 4 mg NRT gum, 4 mg	< 50ng/g < 50 ng/g	EN ISO 17294-2:2016/EN 13805:2014	N/A	Study by researchers at British American Tobacco
Cadmium	Azzopardi <i>et al.</i> , 2021 <sup>78</sup>	NRT lozenge, 4 mg NRT gum, 4 mg	< 10 ng/g 29 ng/g	EN ISO 17294-2:2016/EN 13805:2014	N/A	Study by researchers at British American Tobacco
Chromium	Azzopardi <i>et al.</i> , 2021 <sup>78</sup>	NRT lozenge, 4 mg NRT gum, 4 mg	< 50 – 52 ng/g 743 ng/g DWB	EN ISO 17294-2:2016/EN 13805:2014	N/A	Study by researchers at British American Tobacco

**Table 5. The lifetime cancer risk of 14 categories of nicotine products.** The lifetime cancer risk data is listed by product for 15 categories of product, including two sub-categories of nicotine replacement therapy (inhalable and ingestible). Data completeness, cancer potency, assumed consumption, lifetime cancer risk and number of excess cancer cases per 100,000 are listed. For bidis, cut tobacco, cigarillos, cigars and water pipe tobacco, data gaps were filled with data points from combustible cigarette emissions, the percentages italicized in brackets represent the data completeness without the assumption from combustible cigarette emissions.

Nicotine Product	Data completeness	Cancer potency	Assumed consumption	Lifetime cancer risk	Number of excess cancer cases per 100,000
Combustible cigarettes	100%	0.938223937	15 sticks/day	$3.518 \times 10^{-3}$	3,518
Bidis	100% (8.3%)	0.933721837	15 sticks/day	$3.501 \times 10^{-3}$	3,501
Cut tobacco	100% (41.7%)	0.924185025	15 sticks/day	$3.466 \times 10^{-3}$	3,466
Cigarillos	100% (50%)	0.94625437	5.4 cigarillos/day	$2.938 \times 10^{-3}$	2,938
Cigars	100% (50%)	0.932860468	4 cigars/day	$1.772 \times 10^{-3}$	1,772
Water pipe tobacco	100% (58.3%)	0.944648917	3 sessions/week	$1.748 \times 10^{-3}$	1,748
Smokeless (rest of world)	100%	1.098933857	12 g/day	$1.014 \times 10^{-4}$	101
Heat-not-burn tobacco	100%	0.030355398	15 sticks/day	$1.594 \times 10^{-4}$	159
Electronic cigarettes	100%	0.029237822	163 puffs/day	$1.199 \times 10^{-4}$	120
U.S. dipping tobacco	100%	0.129935871	12 g/day	$1.199 \times 10^{-5}$	12
U.S. chewing tobacco	100%	0.073130229	12 g/day	$6.750 \times 10^{-6}$	6.8
Snus	100%	0.031537993	12 g/day	$2.911 \times 10^{-6}$	2.9
Non-tobacco pouches	100%	0.002410286	12 g/day	$2.225 \times 10^{-7}$	0.2
Nicotine inhalator	25%	0.0004474	6 cartridges/day	$5.369 \times 10^{-6}$	5.4
Nicotine gum/lozenge	100%	0.004920257	12 g/day	$4.542 \times 10^{-7}$	0.5

U.S. chewing tobacco and snus have values of 26.4, 14.9 and 6.4, respectively. The non-tobacco pouches have displaced NRT at the bottom of the scale with a relative score of 0.5. This is due to new data uncovered in this iteration reporting higher values of chromium and cadmium for nicotine gum, compared with non-tobacco nicotine pouches. However, it should be noted that most of the lower data points for both products (non-tobacco nicotine pouches and NRT) are below the limit of detection of the instruments. In these cases, we use the limit of detection as the lower limit, but this may be an overestimation and it is not possible to accurately quantitate these products relative to each other on the scale.


### Epidemiological analysis

In total, 151 risk ratios across 12 categories of nicotine products were included in the epidemiological analysis, compared with 101 risk ratios across eight categories of nicotine products in the 2020 iteration. Heat-not-burn, non-tobacco pouches and cigarillos are not represented in the epidemiological analysis.

In this update, new data has been added for NRT, electronic cigarettes, smokeless (rest of world), bidis, snus, U.S. chewing tobacco, U.S. dipping tobacco, water pipe tobacco and western pipe tobacco. Meta-analyses of cancer and non-cancer outcomes for each nicotine product were conducted and are presented in Table 6.

The completeness of the epidemiological data ranges from 33% for smokeless (rest of world), water pipe tobacco and electronic cigarettes to 100% for combustible cigarettes, cut tobacco, cigars and snus. More complete datasets are representative of the relative risk for a wider range of diseases, whereas less complete datasets generally represent a narrower range. While there is significant overlap in the diseases represented for most products, there remain significant gaps in the dataset for certain products.

For cancer outcomes, the products with the highest risk ratios are smokeless (rest of world) (RR 3.675, CI 95% 1.166 – 11.585),



**Figure 2. The lifetime cancer risk of 14 categories of nicotine products relative to nicotine replacement therapy (NRT).** The lifetime cancer risk of each nicotine product is shown here relative to NRT. The error bars on the chart represent the ranges of toxin emissions for different variants of each product. The color of the bars represents the data completeness, with darker bars denoting more complete datasets.

combustible cigarettes (RR 2.964, CI 95% 1.579 – 5.565) and cut tobacco (RR 2.964, CI 95% 1.579 – 5.565), followed by bidis (RR 2.884, CI 95% 1.75 – 4.752), water pipe tobacco (RR 2.639, CI 95% 1.635 – 4.258), western pipe tobacco (RR 1.924, CI 95% 1.345 – 2.751) and cigars (RR 1.672, CI 95% 1.218 – 2.295) (Figure 3). In all cases, users of these products have a statistically significant risk of cancer compared to non-users of nicotine products. The risk ratios associated with dipping tobacco (RR 1.31, CI 95% 0.685 – 2.503) and chewing tobacco (RR 1.205, CI 95% 0.906 – 1.601) are above one, but the lower limit of the 95% confidence interval is below one, meaning that these products are not associated with a significantly higher risk than non-use of nicotine products. The same is true for NRT (RR 1.017, CI 95% 0.977 – 1.058) and snus (RR 0.998, CI 95% 0.902 – 1.104). All four of these reduced risk products also have  $p$ -values  $> 0.05$ .

For non-cancer risk, the order is slightly different compared with cancer risk. Combustible cigarettes and cut tobacco (RR 1.941, CI 95% 1.676 – 2.248) occupy the highest position, followed by water pipe tobacco (RR 1.83, CI 95% 1.095 – 3.057), bidis (RR 1.708, CI 95% 1.542 – 1.891) and western pipe tobacco (RR 1.707, CI 95% 1.363 – 2.139). Further down the chart are snus (RR 1.242, CI 95% 1.007 – 1.533), U.S. chewing tobacco (RR 1.207, CI 95% 1.119 – 1.301), cigars (RR 1.202, CI 95% 1.077 – 1.341) and the smokeless (rest of world) category

(RR 1.166, CI 95% 1.08 – 1.258). Finally, the lowest risk ratios are for U.S. dipping tobacco (RR 1.063, CI 95% 0.881 – 1.282) and electronic cigarettes (RR 0.908, CI 95% 0.666 – 1.238). The non-cancer risk for all products is statistically significant, except for the U.S. dipping tobacco and electronic cigarettes category.

#### Relative risk hierarchy


The combined risk scores were derived by integrating the LCR and epidemiological analyses and plotting them on a scale from 0 to 100, with 0 representing non-users of any nicotine products and 100 representing users of combustible cigarettes (Figure 4).

Combustible products are associated with the highest risk scores ranging from 40 to 100, with combustible cigarettes at 100, cut tobacco at 99, bidis at 93, cigarillos at 84, water pipe tobacco at 66, western pipe tobacco at 61 and cigars at 40. This high toxicity part of the relative risk hierarchy also includes the smokeless (rest of world) category with a score of 51. All of the products in this higher part of the hierarchy, marked with red bars in Figure 4, have error bars that overlap with other high risk products, and carry a significantly higher risk compared with products in the lower part of the hierarchy (marked by green bars in Figure 4). With relative risk scores of less than 10, the lower part of the hierarchy includes U.S.


**Table 6. Meta-analysis of the epidemiological data for 12 nicotine products.** The risk ratios relative to non-users of any nicotine products, with their confidence intervals in parentheses, and p-values thereof are listed for each nicotine product, accompanied by the full list of component indications for each risk ratio and a data completeness percentage. The data completeness represents the percentage of indication groups with data available. The p-values in bold denote statistically significant (p<0.05) risk compared with non-use of any nicotine product. Italization of the percentage for cut tobacco denotes the assumption of odds ratios of combustible cigarettes in the place of a lack of data.

CANCER RISK			Meta-analysis	
Nicotine Product	Data completeness	Component diseases	Risk ratio (95% confidence intervals)	p-value
Combustible cigarettes	100%	Oral cancer, oropharyngeal cancer, mouth cancer, cancers of the upper aero-digestive tract, head and neck cancer, larynx cancer, esophageal cancer, hypopharyngeal cancer, lung cancer, pancreatic cancer, stomach cancer, bladder cancer, rectal cancer, liver cancer, cardia cancer, cervical cancer, non-Hodgkin's lymphoma, acute lymphoblastic leukemia, acute myeloid lymphoma, cancer mortality	2.964 (1.579 – 5.565)	<b>p = 0.001</b>
Cut tobacco	100% (0%)	Oral cancer, oropharyngeal cancer, mouth cancer, cancers of the upper aero-digestive tract, head and neck cancer, larynx cancer, esophageal cancer, hypopharyngeal cancer, lung cancer, pancreatic cancer, stomach cancer, bladder cancer, rectal cancer, liver cancer, cardia cancer, cervical cancer, non-Hodgkin's lymphoma, acute lymphoblastic leukemia, acute myeloid lymphoma, cancer mortality	2.964 (1.579 – 5.565)	<b>p = 0.001</b>
Water pipe tobacco	33.3%	Oral cancer, oropharyngeal cancer, head and neck cancer	2.639 (1.635 – 4.258)	<b>p &lt; 0.0001</b>
Western Pipe Tobacco	100%	Oropharyngeal cancer, cancers of the upper aero-digestive tract, head and neck cancer, esophageal cancer, lung cancer, pancreatic cancer, stomach cancer, bladder cancer, colorectal cancer, liver cancer, kidney cancer, acute lymphoblastic leukemia, acute myeloid lymphoma, all-cancer, cancer mortality	1.924 (1.345 – 2.751)	<b>p &lt; 0.0001</b>
U.S. dipping tobacco	66.7%	Oral cancer, head and neck cancer, pancreatic cancer, liver cancer, cancer mortality	1.31 (0.685 – 2.503)	p = 0.414
U.S. chewing tobacco	83.3%	Oral cancer, head and neck cancer, pancreatic cancer, liver cancer, cancer mortality	1.205 (0.906 – 1.601)	p = 0.2
Cigars	100%	Oral cancer, oropharyngeal cancer, mouth cancer, lip cancer, tongue cancer, head and neck cancer, larynx cancer, esophageal cancer, lung cancer, pancreatic cancer, stomach cancer, bladder cancer, colorectal cancer, liver cancer, kidney cancer, cancer mortality	1.672 (1.218 – 2.295)	<b>p = 0.001</b>
Snus	100%	Oral cancer, oropharyngeal cancer, esophageal cancer, lung cancer, pancreatic cancer, stomach cancer, bladder cancer, rectal cancer, anal cancer, cardia cancer, acute myeloid lymphoma, chronic myeloid leukemia, multiple myeloma, cancer mortality	0.998 (0.902 – 1.104)	p = 0.97
Smokeless (rest of world)	33.3%	Oral cancer, mouth cancer, laryngeal cancer, hypopharyngeal cancer	3.675 (1.166 – 11.585)	<b>p = 0.026</b>
Bidis	66.7%	Oral cancer, cancers of the upper aero-digestive tract, laryngeal cancer, hypopharyngeal cancer, lung cancer, stomach cancer	2.884 (1.750 – 4.752)	<b>p &lt; 0.0001</b>
Nicotine replacement therapy	50%	Lung cancer, gastrointestinal cancer, all-cancer	1.017 (0.977 – 1.058)	p = 0.414

<b>NON-CANCER RISK</b>				
<b>Nicotine Product</b>	<b>Data completeness</b>	<b>Component diseases</b>	<b>Meta-analysis</b>	
			<b>Risk ratio (95% confidence intervals)</b>	<b>p-value</b>
Combustible cigarettes	100%	Myocardial infarction, stroke, CVD, CHD, atrial fibrillation, asthma, asthma attack, bronchitis, wheeze, COPD, CHD mortality, CVD mortality	1.941 (1.676 – 2.248)	<b>p &lt; 0.0001</b>
Cut tobacco	100% (0%)	Myocardial infarction, stroke, CVD, CHD, atrial fibrillation, asthma, asthma attack, bronchitis, wheeze, COPD, CHD mortality, CVD mortality	1.941 (1.676 – 2.248)	<b>p &lt; 0.0001</b>
Western Pipe Tobacco	66.7%	CVD, CHD, CHD mortality, cerebrovascular disease mortality, COPD mortality	1.707 (1.363 – 2.139)	<b>p &lt; 0.0001</b>
U.S. dipping tobacco	100%	CHD, CHD mortality, CVD mortality	1.063 (0.881 – 1.282)	p = 0.525
U.S. chewing tobacco	66.7%	Myocardial infarction, stroke, CHD, CVD, CHD mortality, CVD mortality	1.207 (1.119 – 1.301)	<b>p &lt; 0.0001</b>
Water pipe tobacco	33.3%	Heart disease	1.83 (1.095 – 3.057)	<b>p = 0.021</b>
Cigars	100%	Myocardial infarction, stroke, CVD, CHD, COPD, CHD mortality, CVD mortality, chronic lower respiratory disease mortality, cerebrovascular disease mortality	1.202 (1.077 – 1.341)	<b>p = 0.001</b>
Snus	100%	Myocardial infarction, stroke, CHD, atrial fibrillation, heart disease, asthma, CVD mortality	1.242 (1.007 – 1.533)	<b>p = 0.043</b>
Smokeless (rest of world)	66.7%	Myocardial infarction, stroke, heart disease	1.166 (1.08 – 1.258)	<b>p &lt; 0.0001</b>
Bidis	100%	Myocardial infarction, CVD, COPD	1.708 (1.542 – 1.891)	<b>p &lt; 0.0001</b>
Electronic cigarettes	33.3%	Bronchitis, wheeze	0.908 (0.666 – 1.238)	p = 0.542



**Figure 3. The risk ratios of 12 nicotine products in the epidemiological analysis.** The risk ratios are plotted here on a bar chart with the dark blue bars representing cancer risk and the light blue bars representing non-cancer risk. The error bars represent the 95% confidence intervals. A dashed blue line highlights where the risk ratio is equal to 1, on other words the risk of using the nicotine product is equal to the risk of not using it. Where the error bar crosses this line the risk of using the nicotine product is not statistically significant compared to non-use of any nicotine product.



**Figure 4. The relative risk hierarchy of the 15 categories of nicotine products.** The combined risk scores for the 15 nicotine products are represented on the hierarchy. The combined risk scores were determined by combining the results of the lifetime cancer risk and epidemiological analyses relative to combustible cigarettes, with weighting according to the availability of data for each analysis. The error bars represent a combination of the range of nicotine product emissions from the lifetime cancer risk analysis and the 95% confidence intervals for the epidemiological data. The data completeness scores for each nicotine product category are shown below the x-axis. In cases where data was assumed from another product, the data completeness score without assumed data is shown in brackets. The red bars show the “high risk” category of products and the green bars show the “reduced risk” category of products. Bars with a horizontal line fill (also marked with a plus sign below the x-axis) denote a combined risk score that consists of only epidemiological data, and the bars with a vertical line fill (also marked with an asterisk below the x-axis) denote a score that consists of only toxin emissions/content data.

chewing tobacco at 9, U.S. dipping tobacco at 8, snus at 6, heat-not-burn devices at 5, electronic cigarettes at 3, NRT at 0.4 and non-tobacco nicotine pouches at 0.1.

The data completeness has increased compared to the 2020 iteration, with combustible cigarettes, smokeless (rest of world), cigars, U.S. dipping tobacco, U.S. chewing tobacco and snus now above 75% complete. Bidis, water pipe tobacco and western pipe tobacco are 40–50% complete, with many of the missing data points being filled by the assumption of combustible tobacco values for toxin emissions. Heat-not-burn devices, electronic cigarettes, NRT and non-tobacco pouches are around 50% complete, with the epidemiological analysis accounting for most of the missing data points. As such, their position on the relative risk hierarchy is determined mostly by the LCR analysis. The lowest data completeness scores are cigarillos and cut tobacco, which have only 20% of the data points complete. For cut tobacco, the dataset has mostly been assumed from combustible cigarettes in both the LCR and epidemiological analysis and taking account of this assumption the data completeness score is 100%. For cigarillos, most of the dataset for the LCR (toxin emissions) analysis was assumed from combustible cigarettes and there is no data for this product in the epidemiological analysis. Overall, data completeness has increased from 2020, but there are still significant gaps to fill and therefore, there remains a level of uncertainty due to missing data in the scores of most products.

## Discussion

This update of the nicotine products relative risk assessment adds new data to the analysis, filling in some of the data gaps in the first iteration, and expands its scope to include smokeless tobacco from outside the United States and Europe.

### Comparison with the 2020 relative risk hierarchy

The overall order of products in the relative risk hierarchy is consistent with the original analysis completed in 2020, although some product categories have shifted one place up or down the scale. Notably, western pipe and water pipe tobacco have inverted, as well as U.S. dipping and U.S. chewing tobacco, heat-not-burn and snus, and non-tobacco pouches and NRT. These changes are driven by new data and adjustments to the scope of the categories, for example the limitation of the chewing and dipping tobacco category to U.S. varieties only and the creation of the smokeless (rest of world) and bidis category.

Overall, the data completeness for the epidemiological analysis has increased from 33% in 2020 to 54% in this update and the LCR analysis from 57% to 68% across all the categories of nicotine products. While this is a reasonable increase in the completeness of both analyses, there are still gaps that could affect the position of products in the spectrum moving forward.

In the LCR analysis, the seven highest scoring products have remained in the same position as in the 2020 iteration, and none have changed by more than 1%. Bidis enter the spectrum between combustible cigarettes and cut tobacco, although only one data point was available for the toxin emis-

sions on bidis and the rest of the data was filled based on the assumption that bidis would emit at least the same toxins as a combustible cigarette. The heat-not-burn and electronic cigarette products have shifted higher on the scale in the LCR analysis. This shift can be attributed to incorporation of data from new studies published since 2020 and completion of the data sets, which are now both 100% complete compared to only 91% and 50% previously. The ingestible categories have all shifted slightly higher on the scale, in part due to the change in methodology where ingestible NRT data now serves as the referent. The exception to this is the non-tobacco pouches which have shifted lower due to new data on their toxin content. The rest of world smokeless category enters the scale with a lower LCR than any of the combustible products, but higher than the reduced-risk categories. The range, represented by the error bars, for the smokeless (rest of world) category is very broad, due to the variety of Indian and south Asian smokeless tobacco products that comprise this category and their wide range of measured toxin content. Some products have measured toxin content on par with combustibles, whereas some have toxin contents on par with the lower risk products.

The overall order of the nicotine products in the epidemiological analysis in this update is identical to the 2020 iteration, with the sole exception of cigars which are now above U.S. dipping and chewing tobacco. This change can be explained primarily by the limitation of this category to U.S. varieties of dipping and chewing tobacco, resulting in the removal of data for other types of chewing and dipping tobacco associated with higher risk ratios. This update brings the epidemiological analysis more in line with the order observed for the toxin emissions data, where U.S. dipping and U.S. chewing tobacco are both below cigars and sit much closer to the newer products.

### Comparison with other published literature

This update of the relative risk hierarchy is broadly in agreement with previous work that estimated the relative harms of nicotine products. Compared to the spectrum presented by Nutt and colleagues, the overall order of the products is the same except for pipes, cigars and water pipe tobacco, which in our spectrum appear as water pipe, western pipe and cigars (from highest to lowest)<sup>17</sup>. Another point of divergence is that our spectrum suggests that there is a larger difference in risk between combustibles and other nicotine products. While the risk spectrum of Nutt and colleagues shows a significant drop in risk from cigarettes and small cigars to pipes and other combustibles, followed by an incremental decrease in risk down to electronic cigarettes, followed by a significant drop to NRT, our spectrum shows a high risk across much of the combustible and smokeless (rest of world) categories, with incremental decreases from cigarillos down to cigars, followed by a significant gap between cigars and the other product categories (U.S. chewing and dipping tobacco, snus, heat-not-burn, electronic cigarettes, NRT and non-tobacco pouches). This is more consistent with the division of products proposed by Abrams and colleagues, defining “extreme toxicity” as the combustible categories, “much less harm” as the smokeless tobacco (U.S./European), e-cigarettes and NRT grouping, and then

“no harm” applying to non-users of any products<sup>10</sup>. In agreement with this categorization, we define two categories of products; those associated with high risk and those associated with reduced risk of tobacco-related diseases.

### High risk nicotine products

The high risk nicotine products category includes combustible cigarettes, cut tobacco, bidis, cigarillos, water pipe tobacco, western pipe tobacco, smokeless (rest of world) and cigars. All products in the high risk category have a combined risk score of between 40 and 100, and are associated with significant harm to health supported by the results of both analyses. The higher risk associated with these products is driven by high levels of toxin exposure, which significantly harm their users health.

Cigars occupy the lowest position in the high risk products group at 40. Despite being a combustible product, cigars are often consumed without inhalation into the lungs, which may be a factor determining the lower risk observed in epidemiological analyses. While the epidemiological analysis is based on real-world consumption, the toxin emissions analysis models only the toxin content and number of puffs per day, without accounting for how the toxins are absorbed into the body. On the other hand, the smokeless (rest of world) category shows much higher cancer risk than any of the other products in the epidemiological analysis, compared with the toxin content analysis. This may be driven by the difference in the varieties represented. In the toxin emissions analysis, studies include varieties of Indian smokeless tobacco, betel quid, zarda and gul, whereas in the epidemiological analysis the products represented are nass, mishri, paan/betel quid, pan-tobacco, khaini, zarda, mawa and gutka.

### Reduced risk nicotine products

The reduced risk products are U.S. chewing and dipping tobacco, snus, heat-not-burn, electronic cigarettes, NRT and non-tobacco nicotine pouches. All of these products have a combined risk score of less than 10. The reduced risk category equates to the “much less harm” category defined by Abrams and colleagues, and all products therein carry significantly reduced risk compared with the combustible products. In the epidemiological analysis, the reduced risk products were found to carry a non-statistically significant risk of cancer compared with non-use of any nicotine product, based on the data available. The lifetime cancer risk also shows a significant drop between products in the high risk category and those in the reduced risk category.

### Limitations of the study

This study has a number of limitations, the first of which is the availability of the input data. While there are fewer missing data in this iteration than in the 2020 version, there are still gaps which could give rise to error. For this reason, it is important to interpret the results in the context of the data completeness scores highlighted throughout the presentation of the data. Secondly, there is also a risk of error arising from a lack of accountability of products that have not been studied in the scientific literature. The sample selection bias of this

study determines that we are only able to represent products for which data was available, which may not correlate with what is currently on the market. Thirdly, the study methodology is limited to average consumption patterns and usage of a single nicotine product. Therefore, it does not represent the potential risk associated with higher consumption levels of the products or dual/poly-use of the products. Fourthly, the epidemiological meta-analysis combines odds ratios for several diseases, which effectively generalizes a multitude of diseases to “cancer” and “non-cancer” categories. While generalization of multiple datasets is not unprecedented in meta-analyses, where calculation of odds ratios for all-cause mortality often involves a similar process, it is important to note that these values must be interpreted carefully. For example, if the generalized cancer risk ratio is 2, the lung cancer ratio may still be much higher or the risk for stomach cancer much lower, as is the case for combustible cigarettes. The risk ratios derived here are meaningless at the level of individual diseases and should not be used as an indicator for specific disease risk. Rather they give an indication of the average risk across a wide variety of diseases, when several confounders are accounted for.

### Real-world implications of the relative risk hierarchy

This update of the relative risk hierarchy defines two categories of products, high risk and reduced risk nicotine products. None of the nicotine products assessed in this study were found to have zero risk, and not using any nicotine product would be the only way to eliminate all risks associated with them. However, the results of this analysis are supportive of the potential to reduce harms caused by high-risk nicotine products by switching to reduced risk products. While it is very important to remain vigilant to new data about novel nicotine products, and to be ready to develop these products with a view to reducing health risks further, reduced risk products can be an effective compromise for reducing the harms of nicotine consumption via combustible tobacco, while giving users the freedom to switch from high risk products on their own terms.

There is a growing body of data demonstrating that nicotine replacement can be a powerful tool for smoking cessation while carrying minimal risks to the user. Indeed, NRT is a widely accepted treatment for smoking cessation. There is also accumulating evidence for other low risk products, such as electronic cigarettes, in their potential to help people who would not otherwise succeed with NRT<sup>93</sup>. Beyond the scientific literature, the potential of reduced risk products is further borne out in real-world data. In Sweden, the use of snus rose dramatically between the 1940s and 1960s in the male population and smoking rates decreased sharply<sup>94</sup>. This smoking trend continues to the present day and the smoking rate in Sweden is only 5% of the population, the lowest in Europe, while around 20% still use snus<sup>94</sup>. The result for public health is that in 2020 Swedish men also had the lowest incidence of tobacco-related cancers across Europe<sup>95</sup>.

While this study does not cover the efficacy of reduced risk products for driving smoking cessation, the results are

consistent with the real-world data from Sweden suggesting that switching from high risk to reduced risk nicotine products could lead to a decrease in tobacco-related disease in the long-term.

## Conclusions

This update of the nicotine products relative risk assessment reinforces the conclusions of the first iteration of the study and previous work in this space. Combustible products, as well as the new categories of bidis and smokeless tobacco from the rest of the world, carry the highest risk of tobacco-related disease. At the other end of the spectrum, lower toxicity smokeless and non-combustible nicotine products carry a significantly reduced risk of tobacco-related disease for their users according to the best available evidence.

## Registration of the review

The review protocol is not published in a register but can be found in the previous version of this publication.

## Data availability

Open Science Framework: Extended data for “Nicotine Products Relative Risk Assessment: An Updated Systematic Review and Meta-analysis.” [https://osf.io/pndyu/?view\\_only=5b9e5eacb62043208bb8919cd6fd6dbdf](https://osf.io/pndyu/?view_only=5b9e5eacb62043208bb8919cd6fd6dbdf)

- Supporting Information:
  - Supplement 1: The keywords used in the systematic literature searches
  - Supplement 2: Sensitivity analyses of the weighting system applied to the relative risk hierarchy.
  - Supplement 3: Analysis data points used in the lifetime cancer risk analysis (including those carried over from the 2020 iteration).
  - Supplement 4: Analysis data points used in epidemiological risk analysis
  - Supplement 5: Full list of studies included in the epidemiological and lifetime cancer risk analyses from the 2020 and 2022 iteration
  - Supplement 6: References for the number of puffs assumptions for each inhalable product.
- PRISMA checklists: PRISMA\_2020\_checklist and PRISMA 2020 for abstracts

Data are available under the terms of the [Creative Commons Zero “No rights reserved” data waiver](#) (CC0 1.0 Public domain dedication).

## References

1. World Health Organization: **Report on Global Tobacco Epidemic**. World Health Organization, 2019; 157. [Reference Source](#)
2. UK Department of Health: **Towards a Smokefree Generation A Tobacco Control Plan for England 2 DH ID box Title: Towards a Smokefree Generation-A Tobacco Control Plan for England**. 2017; [cited 2022 Jun 21]. [Reference Source](#)
3. Marshall TR: **The 1964 Surgeon General’s Report and Americans’ Beliefs about Smoking**. *J Hist Med Allied Sci*. 2015; **70**(2): 250–78. [PubMed Abstract](#) | [Publisher Full Text](#)
4. World Health Organization: **WHO report on the global tobacco epidemic 2021: addressing new and emerging products**. 2021; [cited 2022 Jun 21]. [Reference Source](#)
5. Rafferty SM: **Evidence of early tobacco in Northeastern North America?** *J Archaeol Sci*. 2006; **33**(4): 453–458. [Publisher Full Text](#)
6. U.S. Department of Health and Human Services: **The Health Consequences of Smoking - 50 Years of Progress**. 2014. [Reference Source](#)
7. WHO International Agency for Research on Cancer: **IARC Monographs on the Evaluation of Carcinogenic Risks to Humans**. 2007; **89**. [Reference Source](#)
8. Tomar SL, Hecht SS, Jaspers I, et al.: **Oral Health Effects of Combusted and Smokeless Tobacco Products**. *Adv Dent Res*. 2019; **30**(1): 4–10. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
9. Benowitz NL: **Nicotine Addiction**. *N Engl J Med*. 2010; **362**(24): 2295–303. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. Abrams DB, Glasser AM, Pearson JL, et al.: **Harm Minimization and Tobacco Control: Reframing Societal Views of Nicotine Use to Rapidly Save Lives**. *Annu Rev Public Health*. 2018; **39**: 193–213. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
11. The National Institute for Health and Care Excellence: **Tobacco: preventing uptake, promoting quitting and treating dependence**. 2021. [Reference Source](#)
12. Single E: **Harm Reduction as an Alcohol-Prevention Strategy**. *Alcohol Health Res World*. 1996; **20**(4): 239–243. [PubMed Abstract](#) | [Free Full Text](#)
13. Hartmann-Boyce J, Chepkin SC, Ye W, et al.: **Nicotine replacement therapy versus control for smoking cessation**. *Cochrane Database Syst Rev*. 2018; **5**(5): CD000146. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
14. Clarke E, Thompson K, Weaver S, et al.: **Snus: a compelling harm reduction alternative to cigarettes**. *Harm Reduct J*. 2019; **16**(1): 62. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
15. Melikian AA, Hoffmann D: **Smokeless tobacco: a gateway to smoking or a way away from smoking**. *Biomarkers*. 2009; **14** Suppl 1(SUPPL.1): 85–9. [PubMed Abstract](#) | [Publisher Full Text](#)
16. Murkett R, Rugh M, Ding B: **Nicotine products relative risk assessment: a systematic review and meta-analysis**. [version 1; peer review: 1 approved, 1 approved with reservations]. *F1000Res*. 2020; **9**: 1225. [Publisher Full Text](#)
17. Nutt DJ, Phillips LD, Balfour D, et al.: **Estimating the harms of nicotine-containing products using the MCDA approach**. *Eur Addict Res*. 2014; **20**(5): 218–25. [PubMed Abstract](#) | [Publisher Full Text](#)
18. Stephens WE: **Comparing the cancer potencies of emissions from vapourised nicotine products including e-cigarettes with those of tobacco smoke**. *Tob Control*. 2017; **27**(1): 10–7. [PubMed Abstract](#) | [Publisher Full Text](#)
19. Murkett R: **Nicotine Products Relative Risk Assessment: An Updated Systematic Review and Meta-analysis**. 2022; [cited 2022 Aug 16]. [Reference Source](#)
20. Lyon F: **IARC Monographs on the Identification of Carcinogenic Hazards to Humans PREAMBLE IARC Monographs Preamble**. 2019. [Reference Source](#)
21. Jayalekshmi PA, Nandakumar A, Akiba S, et al.: **Associations of Tobacco Use and Alcohol Drinking with Laryngeal and Hypopharyngeal Cancer Risks among Men in Karunagappally, Kerala, India -Karunagappally Cohort Study**. *PLoS One*. 2013; **8**(8): e73716. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Hassan MM, Spitz MR, Thomas MB, et al.: **Effect of different types of smoking**

- and synergism with Hepatitis C virus on risk of hepatocellular carcinoma in American men and women: Case-control study. *Int J Cancer*. 2008; **123**(8): 1883–91.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Ye W, Ekström AM, Hansson LE, et al.: **Tobacco, alcohol and the risk of gastric cancer by sub-site and histologic type.** *Int J Cancer*. 1999; **83**(2): 223–9.  
[PubMed Abstract](#) | [Publisher Full Text](#)
24. Fernberg P, Odenbro A, Bellocco R, et al.: **Tobacco Use, Body Mass Index, and the Risk of Leukemia and Multiple Myeloma: A Nationwide Cohort Study in Sweden.** *Cancer Res*. 2007; **67**(12): 5983–6.  
[PubMed Abstract](#) | [Publisher Full Text](#)
25. Gupta R, Gupta S, Sharma S, et al.: **Association of smokeless tobacco and cerebrovascular accident: a systematic review and meta-analysis of global data.** *J Public Health (Oxf)*. 2020; **42**(2): e150–e157.  
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Alexander M: **Tobacco use and the risk of cardiovascular diseases in developed and developing countries.** 2013.  
[Reference Source](#)
27. Mu G, Wang J, Liu Z, et al.: **Association between smokeless tobacco use and oral cavity cancer risk in women compared with men: a systematic review and meta-analysis.** *BMC Cancer*. 2021; **21**(1): 960.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. Jayalekshmi PA, Hassani S, Nandakumar A, et al.: **Gastric cancer risk in relation to tobacco use and alcohol drinking in Kerala, India -- Karunagappally cohort study.** *World J Gastroenterol*. 2015; **21**(44): 12676–85.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. Braymiller JL, Barrington-Trimis JL, Leventhal AM, et al.: **Assessment of Nicotine and Cannabis Vaping and Respiratory Symptoms in Young Adults.** *JAMA Netw Open*. 2020; **3**(12): e2030189.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
30. Hansson J, Pedersen NL, Galanti MR, et al.: **Use of snus and risk for cardiovascular disease: results from the Swedish Twin Registry.** *J Intern Med*. 2009; **265**(6): 717–24.  
[PubMed Abstract](#) | [Publisher Full Text](#)
31. Hergens MP, Galanti R, Hansson J, et al.: **Use of scandinavian moist smokeless tobacco (snus) and the risk of atrial fibrillation.** *Epidemiology*. 2014; **25**(6): 872–6.  
[PubMed Abstract](#) | [Publisher Full Text](#)
32. Lee PN: **Summary of the epidemiological evidence relating snus to health.** *Regul Toxicol Pharmacol*. 2011; **59**(2): 197–214.  
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Araghi M, Galanti MR, Lundberg M, et al.: **No association between moist oral snuff (snus) use and oral cancer: pooled analysis of nine prospective observational studies.** *Scand J Public Health*. 2021; **49**(8): 833–40.  
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Boffetta P, Aagnes B, Weiderpass E, et al.: **Smokeless tobacco use and risk of cancer of the pancreas and other organs.** *Int J Cancer*. 2005; **114**(6): 992–5.  
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Araghi M, Rosaria Galanti M, Lundberg M, et al.: **Use of moist oral snuff (snus) and pancreatic cancer: Pooled analysis of nine prospective observational studies.** *Int J Cancer*. 2017; **141**(4): 687–693.  
[PubMed Abstract](#) | [Publisher Full Text](#)
36. Nordenvall C, Nilsson PJ, Ye W, et al.: **Smoking, snus use and risk of right- and left-sided colon, rectal and anal cancer: a 37-year follow-up study.** *Int J Cancer*. 2011; **128**(1): 157–65.  
[PubMed Abstract](#) | [Publisher Full Text](#)
37. Byhamre ML, Araghi M, Alfreðsson L, et al.: **Swedish snus use is associated with mortality: a pooled analysis of eight prospective studies.** *Int J Epidemiol*. 2021; **49**(6): 2041–2050.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
38. Malhotra J, Borron C, Freedman ND, et al.: **Association between Cigar or Pipe Smoking and Cancer Risk in Men: A Pooled Analysis of Five Cohort Studies.** *Cancer Prev Res (Phila)*. 2017; **10**(12): 704–709.  
[PubMed Abstract](#) | [Publisher Full Text](#)
39. Islami F, Pourshams A, Vedanthan R, et al.: **Smoking water-pipe, chewing nass and prevalence of heart disease: a cross-sectional analysis of baseline data from the Golestan Cohort Study, Iran.** *Heart*. 2013; **99**(4): 272–8.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
40. Etemadi A, Khademi H, Kamangar F, et al.: **Hazards of cigarettes, smokeless tobacco and waterpipe in a Middle Eastern Population: a Cohort Study of 50 000 individuals from Iran.** *Tob Control*. 2017; **26**(6): 674–682.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
41. Gupta PC, Pednekar MS, Parkin DM, et al.: **Tobacco associated mortality in Mumbai (Bombay) India. Results of the Bombay Cohort Study.** *Int J Epidemiol*. 2005; **34**(6): 1395–402.  
[PubMed Abstract](#) | [Publisher Full Text](#)
42. Ayo-Yusuf OA, Reddy PS, van den Borne BW: **Association of snuff use with chronic bronchitis among South African women: implications for tobacco harm reduction.** *Tob Control*. 2008; **17**(2): 99–104.  
[PubMed Abstract](#) | [Publisher Full Text](#)
43. Asthana S, Vohra P, Labani S: **Association of smokeless tobacco with oral cancer: A review of systematic reviews.** *Tob Prev Cessat*. 2019; **5**: 34.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
44. Sankaranarayanan R, Duffy SW, Padmakumary G, et al.: **Tobacco chewing, alcohol and nasal snuff in cancer of the gingiva in Kerala, India.** *Br J Cancer*. 1989; **60**(4): 638–43.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
45. Sapkota A, Gajalakshmi V, Jetly DH, et al.: **Smokeless tobacco and increased risk of hypopharyngeal and laryngeal cancers: A multicentric case-control study from India.** *Int J Cancer*. 2007; **121**(8): 1793–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
46. Teo KK, Ounpuu S, Hawken S, et al.: **Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study.** *Lancet*. 2006; **368**(9536): 647–58.  
[PubMed Abstract](#) | [Publisher Full Text](#)
47. Duong ML, Rangarajan S, Zhang X, et al.: **Effects of bidi smoking on all-cause mortality and cardiorespiratory outcomes in men from south Asia: an observational community-based substudy of the Prospective Urban Rural Epidemiology Study (PURE).** *Lancet Glob Health*. 2017; **5**(2): e168–76.  
[PubMed Abstract](#) | [Publisher Full Text](#)
48. Jayalekshmi PA, Gangadharan P, Akiba S, et al.: **Oral cavity cancer risk in relation to tobacco chewing and bidi smoking among men in Karunagappally, Kerala, India: Karunagappally cohort study.** *Cancer Sci*. 2011; **102**(2): 460–7.  
[PubMed Abstract](#) | [Publisher Full Text](#)
49. Jayalekshmy PA, Akiba S, Nair MK, et al.: **Bidi smoking and lung cancer incidence among males in Karunagappally cohort in Kerala, India.** *Int J Cancer*. 2008; **123**(6): 1390–7.  
[PubMed Abstract](#) | [Publisher Full Text](#)
50. Murray RP, Connett JE, Zapawa LM: **Does nicotine replacement therapy cause cancer? Evidence from the Lung Health Study.** *Nicotine Tob Res*. 2009; **11**(9): 1076–82.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
51. Murphy J, Liu C, McAdam K, et al.: **Assessment of tobacco heating product THP1.0. Part 9: The placement of a range of next-generation products on an emissions continuum relative to cigarettes via pre-clinical assessment studies.** *Regul Toxicol Pharmacol*. 2018; **93**: 92–104.  
[PubMed Abstract](#) | [Publisher Full Text](#)
52. Tayyarah R, Long GA: **Comparison of select analytes in aerosol from e-cigarettes with smoke from conventional cigarettes and with ambient air.** *Regul Toxicol Pharmacol*. 2014; **70**(3): 704–10.  
[PubMed Abstract](#) | [Publisher Full Text](#)
53. Appel BR, Guirguis G, Kim IS, et al.: **Benzene, benzo(a)pyrene, and lead in smoke from tobacco products other than cigarettes.** *Am J Public Health*. 1990; **80**(5): 560–4.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
54. Song MA, Marian C, Brasky TM, et al.: **Chemical and Toxicological Characteristics of Conventional and Low-TSNA Moist Snuff Tobacco Products.** *Toxicol Lett*. 2016; **245**: 68–77.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
55. Richter P, Hodge K, Stanfill S, et al.: **Surveillance of moist snuff: total nicotine, moisture, pH, un-ionized nicotine, and tobacco-specific nitrosamines.** *Nicotine Tob Res*. 2008; **10**(11): 1645–52.  
[PubMed Abstract](#) | [Publisher Full Text](#)
56. Stepanov I, Jensen J, Hatsukami D, et al.: **Tobacco-specific nitrosamines in new tobacco products.** *Nicotine Tob Res*. 2006; **8**(2): 309–13.  
[PubMed Abstract](#) | [Publisher Full Text](#)
57. Margham J, McAdam K, Forster M, et al.: **Chemical Composition of Aerosol from an E-Cigarette: A Quantitative Comparison with Cigarette Smoke.** *Chem Res Toxicol*. 2016; **29**(10): 1662–78.  
[PubMed Abstract](#) | [Publisher Full Text](#)
58. Belushkin M, Tabin Djoko D, Esposito M, et al.: **Selected Harmful and Potentially Harmful Constituents Levels in Commercial e-Cigarettes.** *Chem Res Toxicol*. 2020; **33**(2): 657–68.  
[PubMed Abstract](#) | [Publisher Full Text](#)
59. Laugesen M: **Ruyan® e-cigarette Cartridge Report.** Christchurch; 2008; [cited 2022 Jul 13].  
[Reference Source](#)
60. Li Y, Burns AE, Tran LN, et al.: **Impact of e-Liquid Composition, Coil Temperature, and Puff Topography on the Aerosol Chemistry of Electronic Cigarettes.** *Chem Res Toxicol*. 2021; **34**(6): 1640–54.  
[PubMed Abstract](#) | [Publisher Full Text](#)
61. Farsalinos KE, Voudris V, Spyrou A, et al.: **E-cigarettes emit very high formaldehyde levels only in conditions that are aversive to users: A replication study under verified realistic use conditions.** *Food Chem Toxicol*. 2017; **109**(Pt 1): 90–94.  
[PubMed Abstract](#) | [Publisher Full Text](#)
62. Salamanca JC, Meehan-Atrash J, Vreeke S, et al.: **E-cigarettes can emit formaldehyde at high levels under conditions that have been reported to be non-averse to users.** *Sci Rep*. 2018; **8**(1): 7559.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
63. Nicol J, Fraser R, Walker L, et al.: **Comprehensive Chemical Characterization of the Aerosol Emissions of a Vaping Product Based on a New Technology.** *Chem Res Toxicol*. 2020; **33**(3): 789–799.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
64. Geiss O, Bianchi I, Barahona F, et al.: **Characterisation of mainstream and**

- passive vapours emitted by selected electronic cigarettes. *Int J Hyg Environ Health*. 2015; **218**(1): 169–80.  
[PubMed Abstract](#) | [Publisher Full Text](#)
65. Son Y, Bhattarai C, Samburova V, *et al.*: **Carbonyls and Carbon Monoxide Emissions from Electronic Cigarettes Affected by Device Type and Use Patterns.** *Int J Environ Res Public Health*. 2020; **17**(8): 2767.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
66. Chen JY, Canchola A, Lin YH: **Carbonyl composition and electrophilicity in vaping emissions of flavored and unflavored E-liquids.** *Toxics*. 2021; **9**(12): 345.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
67. Landmesser A, Scherer M, Scherer G, *et al.*: **Assessment of the potential vaping-related exposure to carbonyls and epoxides using stable isotope-labeled precursors in the e-liquid.** *Arch Toxicol*. 2021; **95**(8): 2667–2676.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
68. Nyakutsikwa B, Britton J, Bogdanovica I, *et al.*: **Characterising vaping products in the United Kingdom: an analysis of Tobacco Products Directive notification data.** *Addiction*. 2021; **116**(9): 2521–2528.  
[PubMed Abstract](#) | [Publisher Full Text](#)
69. Farsalinos KE, Yannovits N, Sarri T, *et al.*: **Carbonyl emissions from a novel heated tobacco product (IQOS): comparison with an e-cigarette and a tobacco cigarette.** *Addiction*. 2018; **113**(11): 2099–2106.  
[PubMed Abstract](#) | [Publisher Full Text](#)
70. Lee MS, LeBouf RF, Son YS, *et al.*: **Nicotine, aerosol particles, carbonyls and volatile organic compounds in tobacco- and menthol-flavored e-cigarettes.** *Environ Health*. 2017; **16**(1): 42.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
71. Schaller JP, Keller D, Poget L, *et al.*: **Evaluation of the Tobacco Heating System 2.2. Part 2: Chemical composition, genotoxicity, cytotoxicity, and physical properties of the aerosol.** *Regul Toxicol Pharmacol*. 2016; **81**(Suppl 2): S27–S47.  
[PubMed Abstract](#) | [Publisher Full Text](#)
72. Li X, Luo Y, Jiang X, *et al.*: **Chemical Analysis and Simulated Pyrolysis of Tobacco Heating System 2.2 Compared to Conventional Cigarettes.** *Nicotine Tob Res*. 2019; **21**(1): 111–118.  
[PubMed Abstract](#) | [Publisher Full Text](#)
73. Forster M, Fiebelkorn S, Yurteri C, *et al.*: **Assessment of novel tobacco heating product THP1.0. Part 3: Comprehensive chemical characterisation of harmful and potentially harmful aerosol emissions.** *Regul Toxicol Pharmacol*. 2018; **93**: 14–33.  
[PubMed Abstract](#) | [Publisher Full Text](#)
74. Mallock N, Böss L, Burk R, *et al.*: **Levels of selected analytes in the emissions of “heat not burn” tobacco products that are relevant to assess human health risks.** *Arch Toxicol*. 2018; **92**(6): 2145–2149.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
75. Salman R, Talih S, El-Hage R, *et al.*: **Free-Base and Total Nicotine, Reactive Oxygen Species, and Carbonyl Emissions From IQOS, a Heated Tobacco Product.** *Nicotine Tob Res*. 2019; **21**(9): 1285–1288.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
76. Kim YH, An YJ, Shin JW: **Carbonyl Compounds Containing Formaldehyde Produced from the Heated Mouthpiece of Tobacco Sticks for Heated Tobacco Products.** *Molecules*. 2020; **25**(23): 5612.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
77. Azzopardi D, Liu C, Murphy J: **Chemical characterization of tobacco-free “modern” oral nicotine pouches and their position on the toxicant and risk continuums.** *Drug Chem Toxicol*. 2021; 1–9.  
[PubMed Abstract](#) | [Publisher Full Text](#)
78. Wu W, Song S, Ashley DL, *et al.*: **Assessment of tobacco-specific nitrosamines in the tobacco and mainstream smoke of Bidi cigarettes.** *Carcinogenesis*. 2004; **25**(2): 283–7.  
[PubMed Abstract](#) | [Publisher Full Text](#)
79. Idris AM, Nair J, Ohshima H, *et al.*: **Unusually high levels of carcinogenic tobacco-specific nitrosamines in Sudan snuff (toombak).** *Carcinogenesis*. 1991; **12**(6): 1115–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
80. Stepanov I, Gupta PC, Dhupal G, *et al.*: **High levels of tobacco-specific N-nitrosamines and nicotine in Chaini Khaini, a product marketed as snus.** *Tob Control*. 2015; **24**(E4): e271.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
81. Nasrin S, Chen G, Watson CJW, *et al.*: **Comparison of tobacco-specific nitrosamine levels in smokeless tobacco products: High levels in products from Bangladesh.** *PLoS One*. 2020; **15**(5): e0233111.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
82. Al-Mukhaini N, Ba-Omar T, Eltayeb EA, *et al.*: **Analysis of Tobacco-Specific Nitrosamines in the Common Smokeless Tobacco Afzal in Oman.** *Sultan Qaboos Univ Med J*. 2016; **16**(1): e20–6.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
83. Stepanov I, Gupta PC, Parascandola M, *et al.*: **Constituent Variations in Smokeless Tobacco Purchased in Mumbai, India.** *Tob Regul Sci*. 2017; **3**(3): 305–314.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
84. Orisakwe OE, Igweze ZN, Okolo KO, *et al.*: **Human health hazards of poly aromatic hydrocarbons in Nigerian smokeless tobacco.** *Toxicol Rep*. 2015; **2**: 1019–1023.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
85. Al-Rmalli SW, Jenkins RO, Haris PI: **Betel quid chewing elevates human exposure to arsenic, cadmium and lead.** *J Hazard Mater*. 2011; **190**(1–3): 69–74.  
[PubMed Abstract](#) | [Publisher Full Text](#)
86. Brima EI: **Determination of Metal Levels in Shamma (Smokeless Tobacco) with Inductively Coupled Plasma Mass Spectrometry (ICP-MS) in Najran, Saudi Arabia.** *Asian Pac J Cancer Prev*. 2016; **17**(10): 4761–4767.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
87. Zakiullah, Saeed M, Muhammad N, *et al.*: **Assessment of potential toxicity of a smokeless tobacco product (naswar) available on the Pakistani market.** *Tob Control*. 2012; **21**(4): 396–401.  
[PubMed Abstract](#) | [Publisher Full Text](#)
88. Hossain MT, Hassi U, Imamul Huq SM: **Assessment of concentration and toxicological (Cancer) risk of lead, cadmium and chromium in tobacco products commonly available in Bangladesh.** *Toxicol Rep*. 2018; **5**: 897–902.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
89. Orisakwe OE, Igweze ZN, Okolo KO, *et al.*: **Heavy metal hazards of Nigerian smokeless tobacco.** *Tob Control*. 2014; **23**(6): 513–7.  
[PubMed Abstract](#) | [Publisher Full Text](#)
90. Prabhakar V, Jayakrishnan G, Nair SV, *et al.*: **Determination of Trace Metals, Moisture, pH and Assessment of Potential Toxicity of Selected Smokeless Tobacco Products.** *Indian J Pharm Sci*. 2013; **75**(3): 262–9.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
91. Guezguez F, Abdelwaheb M, Anane I, *et al.*: **Chemical characteristics and cancer risk assessment of smokeless tobacco used in Tunisia (neffa).** *Pan Afr Med J*. 2021; **40**(47): 45.  
[PubMed Abstract](#) | [Free Full Text](#)
92. Hajek P, Phillips-Waller A, Przulj D, *et al.*: **A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy.** *N Engl J Med*. 2019; **380**(7): 629–37.  
[PubMed Abstract](#) | [Publisher Full Text](#)
93. Ramström L, Borland R, Wikmans T: **Patterns of Smoking and Snus Use in Sweden: Implications for Public Health.** *Int J Environ Res Public Health*. 2016; **13**(11): 1110.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
94. Clarke E, Thompson K, Weaver S, *et al.*: **Snus: a compelling harm reduction alternative to cigarettes.** *Harm Reduct J*. 2019; **16**(1): 62.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
95. Ferlay J, Ervik M, Lam F, *et al.*: **Global Cancer Observatory: Cancer Today.** Lyon, France: International Agency for Research on Cancer. 2020; accessed [15 August 2022].  
[Reference Source](#)

## Open Peer Review

Current Peer Review Status:  

### Version 1

Reviewer Report 19 August 2022

<https://doi.org/10.5256/f1000research.29550.r145985>

© 2022 Sarkar M et al. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Mohamadi Sarkar** 

Center for Research and Technology, Altria Client Services LLC, Richmond, VA, USA

**Chastain Anderson**

Altria Client Services LLC, Richmond, VA, USA

**Thaddeus Hannel**

Altria Client Services LLC, Richmond, VA, USA

**Brendan Noggle**

Center for Research and Technology, Altria Client Services LLC, Richmond, VA, USA

We read the manuscript submitted by Murkett *et al* in F1000Research with great interest. The authors present relative risk hierarchy (RRH) of 13 nicotine products based on a systematic review of the scientific literature and analysis of the evidence. The authors derive a combined risk score, for each nicotine product, on an arbitrary scale of 0-100 (low to high risk) based on weighted lifetime cancer risk (LCR) estimates (derived from the toxic emissions) and epidemiological data. The proposed RRH method provides a useful framework for ranking different categories of nicotine products including conventional and novel tobacco products as well as nicotine replacement therapy products. However, there are some major limitations in the analysis and interpretation of the evidence. We believe that the authors consider revising the manuscript, based on the following comments, before it can be approved.

First, for many products there is no reliable and consistent epidemiological evidence available on long-term health risks. Therefore, estimating a combined risk score and presenting on the same scale as products that do have epidemiological evidence is inappropriate and could lead to inaccurate conclusions.

In this study, the authors estimate the combined risk score for the different tobacco product categories based on weighted lifetime cancer risk estimates and epidemiological analysis of cancer and non-cancer risks. The data are first converted to an arbitrary scale from 0 to 100. The authors then calculate the combined risk score by applying 5:3 weighting to the scaled lifetime cancer risk result and scaled epidemiological results. The authors present sensitivity analysis based on different proportions of weightings of the data (1:1 and 3:5). As evident from the RRH

sensitivity analysis presented in supplement 4, there being no epidemiological data available for the novel tobacco products, the weighting applied in the final RRH result appears to be 1:0 (lifetime cancer risk : epidemiological risk). In charts a-c of supplement 4, the RRH value remains unchanged for products without epidemiological data, likely because the weighting for these products is fixed to 1:0. In our opinion, the authors should not include products for which there is no epidemiological data (or no lifetime cancer risk data) on the same plot with products which have been weighted from both sources of study data. Moreover, combining these scales with the existing epidemiological gaps assumes that the risk score is determined by the lifetime cancer risk alone which is not likely to be true and can lead to inaccurate conclusions. That said, we understand the challenge of estimating the combined risk score in the absence of epidemiological evidence for the novel tobacco products. Perhaps the authors could overcome such data gaps by inferring the long-term health risks by bridging to the epidemiological evidence for other comparable products. For example, the existing epidemiology on smokeless tobacco products, including snus, can inform the long-term health risks of modern oral nicotine products, due to the similar oral route of exposure. Such innovative oral products contain no, or substantially reduced, levels of toxicants e.g. tobacco specific nitrosamine. Therefore, the long-term health risks would at minimum be comparable or even lower than smokeless tobacco products. We recommend that authors not include products with epidemiological data alongside products without epidemiological evidence. Such an “apples to oranges” comparison lacks scientific robustness and could result in inaccurate conclusions. The authors may derive the long-term health risks for innovative products where epidemiological evidence does not exist (e.g. modern oral products) by bridging to published epidemiology on similar products (e.g. smokeless tobacco products).

We understand the utility of the RRH framework and, as such, if the authors must include Figure 4, then alternatively we recommend that the authors clearly denote the products without epidemiological data in a lighter bar with shaded fill and clearly state the differences between the products with, and without, epidemiological evidence. The figure legends should also clearly explain the method used to estimate these combined risk scores.

Second, the lifetime cancer risk calculated based on toxin emissions or content data for the inhalable and ingestible nicotine products, while reasonable, has some limitations.

The authors state that cancer risk for inhalable products was estimated based on the method reported by Stephens 2017, while cancer risk estimate for oral products was estimated via the EPA Risk Assessment Guidance for Superfund (RAGS) methodology used by the FDA (FDA 2017). However, a closer examination of the approach outlined by the authors in the manuscript indicates that the equations used in the manuscript differ from the equations cited in Stephens (reference #9 of the manuscript). Additionally, it is unclear as to why two different methods of assessing cancer risk are used when the RAGS methodology can be applied to both inhalable and oral products and a harmonized approach may provide a better basis for comparison across product categories. This study would be significantly strengthened by providing a more detailed description of the approach to calculating cancer potency, including: 1) a justification as to why the individual toxicants chosen are representative of the cancer risk of the products; 2) the OEHHA unit risk values sourced for each individual toxicant; and 3) a more detailed description of any modification to the method used by Stephens for calculating product cancer potency. Overall, we recommend that authors provide all the underlying data and calculations for others to replicate their analysis.

Additionally, we note that the authors have not considered the biomarkers of exposure in their analysis adequately enough. Biomarkers of exposure may provide direct evidence of harmful and potentially harmful constituent (HPHC) exposure since these studies incorporate actual human use of tobacco products and account for factors that cannot be replicated in *in vitro* studies, including differences in routes of administration, absorption, distribution, metabolism, and excretion. However, the biomarker data in this study is underutilized and limited to supplementary figures.

The figure in Supplement 5, based on the levels of excess biomarkers of exposure for six IARC Group 1 carcinogens and nine non-cancer toxicants, is misleading. The figure mischaracterizes the excess biomarker levels for dipping tobacco. The authors should provide the rationale for limiting the plot only for these select constituents. Particularly, as stated by the authors, "Tobacco smoke contains more than 7,000 chemicals, of which 250 are known to be harmful and 69 are known to cause cancer." Many of the well-characterized toxins and carcinogens are present in the gas phase. The pulmonary toxicity of many of the gas phase constituents found in cigarette smoke are well established; for example, acrolein is an established pulmonary irritant and cilia toxicant, and it impairs lung defenses (Bein & Leikauf, 2011).<sup>1</sup> Given that the dip products are noncombustible and do not expose the user to combustion-related constituents, there is sufficient evidence indicating that smokeless tobacco (ST) users overall have demonstrably lower or no exposure to many of the harmful toxicants present in cigarette smoke. Prasad *et al.*, confirmed the lack of exposure to gas phase HPHCs (Prasad, Jones, Chen, & Gregg, 2016).<sup>2</sup> The authors report that biomarkers of exposure to 1,3-butadiene, acrolein, crotonaldehyde, benzene, and acrylamide were statistically significantly lower in ST users compared to cigarette smokers and not statistically different compared to non-tobacco users. These results were confirmed in another study (Campbell, Brown, Jones, Marano, & Borgerding, 2015), where the authors report no significant differences in biomarkers of acrolein, benzene, pyrene, carbon monoxide, and 1,3-butadiene between ST users and non-tobacco users, and significantly lower levels in ST users relative to cigarette smokers.<sup>3</sup> In a large sample based on NHANES data, biomarkers of exposure to many of other HPHCs (blood cadmium, blood mercury, and urinary arsenic) were not elevated among ST users compared with non-tobacco users (Rostron, Chang, van Bommel, Xia, & Blount, 2015).<sup>4</sup> Prasad *et al.*, corroborated similar observations related to cadmium (Prasad *et al.*, 2016). Additionally trace metals like chromium, nickel, tin, and selenium were also found to be not significantly different in ST users compared to non-tobacco users (Prasad *et al.*, 2016).

In summary, there is a vast body of evidence indicating that biomarkers assessing exposure to combustion related HPHCs are either absent or present at levels no different than non-tobacco users and significantly lower than cigarette smokers. Therefore, the figure in Supplement 5 is misleading for the dipping tobacco category and we recommend that the authors replot this figure to include harmful and potentially harmful constituents listed by FDA (Food and Drug Administration, 2012) which accurately reflect the current state of the evidence.<sup>5</sup>

Third, the epidemiological risk estimates for dipping are mischaracterized, the authors include risk estimates from use of products from non-US countries, that are vastly different from the US dip product.

While the search criteria for the literature review on epidemiological evidence is reasonable, the authors do not accurately characterize the disease risks from the use of US dip. The study identifies dip risk from a mix of U.S., European, *and* some global cancer risk estimates as 2.06 (1.38 – 3.09) and non-cancer risk as 1.305 (1.15 – 1.48). The authors conflate the disease risk estimates

from other countries where the smokeless tobacco (ST) products are vastly different from the US products. For example, some of the smokeless tobacco products available in South East Asia have levels of TSNA that are several-fold higher than US dip, up to 516,000 ng/g product (Stanfill *et al.*, 2011).<sup>6</sup> These differences may account for the higher disease burden observed in South East Asian countries like India and Pakistan. For example, in a meta-analysis Siddiqi *et al.* (Siddiqi *et al.*, 2015) estimated the overall relative risk (RR) for mouth cancer from ST use as 5.12 (95% CI 3.27-8.02) for India and 8.81 (95% 3.14-24.69) for Pakistan.<sup>7</sup> In contrast, as reported by the authors, oral cancer risk estimates for North America are substantially lower, RR = 0.91 (95% CI 0.68-1.25). Furthermore, epidemiological evidence supports a much weaker, and in most cases null, association between smokeless tobacco use and heart diseases. A meta-analysis by Boffetta and Straif found that ST users had slightly elevated risk of myocardial infarction compared to non-ST-users summarizing estimates from studies conducted in the U.S. (RR=1.11, 95% CI=1.04 to 1.19). In this study, authors noted that misclassification of, and thus, confounding by cigarette smoking was possible (Boffetta & Straif, 2009).<sup>8</sup> A later meta-analysis by Vidyasagaran *et al.* reported a null association between ST use and mortality from ischemic heart disease (RR=1.03, 95% CI=0.83 to 1.27) (Vidyasagaran, Siddiqi, & Kanaan, 2016).<sup>9</sup> More recently, Rostron *et al.* updated earlier studies and documented a slightly elevated risk of ischemic heart disease among current ST users (who had never smoked) based on studies conducted in the U.S. (RR=1.17, 95% CI=1.09 to 1.27) (Rostron *et al.*, 2018).<sup>10</sup> With a focus on coronary heart disease, Gupta *et al.* found no elevated risk when comparing ST users with nonusers (RR=1.04, 95% CI=0.83 to 1.24) (Gupta, Gupta, Sharma, Sinha, & Mehrotra, 2019).<sup>11</sup> We note that, overall, the point estimates from the meta-analyses range from 1.03 to 1.17, which were close to null, even when considering the statistically significant summary estimates. Therefore, we recommend that the authors revise their combined risk scores for dip to accurately reflect the source of the epidemiological evidence in their analysis. The authors could display the combined risk scores for the US dip products separately from the smokeless tobacco products used in India and Pakistan.

## BIBLIOGRAPHY

- Bein, K., & Leikauf, G. D. (2011). Acrolein - a pulmonary hazard. *Mol Nutr Food Res*, 55(9), 1342-1360. doi:10.1002/mnfr.201100279
- Boffetta, P., & Straif, K. (2009). Use of smokeless tobacco and risk of myocardial infarction and stroke: systematic review with meta-analysis. *BMJ*, 339, b3060. doi:10.1136/bmj.b3060
- Campbell, L. R., Brown, B. G., Jones, B. A., Marano, K. M., & Borgerding, M. F. (2015). Study of cardiovascular disease biomarkers among tobacco consumers, part 1: biomarkers of exposure. *Inhal Toxicol*, 27(3), 149-156. doi:10.3109/08958378.2015.1013228
- Food and Drug Administration, C. f. T. P. (2012). Draft Guidance: Reporting Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke Under Section 904(a)(3) of the Federal Food, Drug, and Cosmetic Act.
- Gupta, R., Gupta, S., Sharma, S., Sinha, D. N., & Mehrotra, R. (2019). Risk of Coronary Heart Disease Among Smokeless Tobacco Users: Results of Systematic Review and Meta-Analysis of Global Data. *Nicotine Tob Res*, 21(1), 25-31. doi:10.1093/ntr/nty002
- Prasad, G. L., Jones, B. A., Chen, P., & Gregg, E. O. (2016). A cross-sectional study of biomarkers of exposure and effect in smokers and moist snuff consumers. *Clin Chem Lab Med*, 54(4), 633-642. doi:10.1515/cclm-2015-0594
- Rostron, B. L., Chang, C. M., van Bommel, D. M., Xia, Y., & Blount, B. C. (2015). Nicotine and

Toxicant Exposure among U.S. Smokeless Tobacco Users: Results from 1999 to 2012 National Health and Nutrition Examination Survey Data. *Cancer Epidemiol Biomarkers Prev*, 24(12), 1829-1837. doi:10.1158/1055-9965.EPI-15-0376

Rostron, B. L., Chang, J. T., Anic, G. M., Tanwar, M., Chang, C. M., & Corey, C. G. (2018). Smokeless tobacco use and circulatory disease risk: a systematic review and meta-analysis. *Open Heart*, 5(2), e000846. doi:10.1136/openhrt-2018-000846

Siddiqi, K., Shah, S., Abbas, S. M., Vidyasagan, A., Jawad, M., Dogar, O., & Sheikh, A. (2015). Global burden of disease due to smokeless tobacco consumption in adults: analysis of data from 113 countries. *BMC Med*, 13, 194. doi:10.1186/s12916-015-0424-2

Stanfill, S. B., Connolly, G. N., Zhang, L., Jia, L. T., Henningfield, J. E., Richter, P., . . . Watson, C. H. (2011). Global surveillance of oral tobacco products: total nicotine, unionised nicotine and tobacco-specific N-nitrosamines. *Tob Control*, 20(3), e2. doi:10.1136/tc.2010.037465

Vidyasagan, A. L., Siddiqi, K., & Kanaan, M. (2016). Use of smokeless tobacco and risk of cardiovascular disease: A systematic review and meta-analysis. *Eur J Prev Cardiol*, 23(18), 1970-1981. doi:10.1177/2047487316654026

## References

1. Boffetta P, Straif K: Use of smokeless tobacco and risk of myocardial infarction and stroke: systematic review with meta-analysis. *BMJ*. 2009; **339**: b3060 [PubMed Abstract](#) | [Publisher Full Text](#)
2. Prasad GL, Jones BA, Chen P, Gregg EO: A cross-sectional study of biomarkers of exposure and effect in smokers and moist snuff consumers. *Clin Chem Lab Med*. 2016; **54** (4): 633-42 [PubMed Abstract](#) | [Publisher Full Text](#)
3. Campbell LR, Brown BG, Jones BA, Marano KM, et al.: Study of cardiovascular disease biomarkers among tobacco consumers, part 1: biomarkers of exposure. *Inhal Toxicol*. 2015; **27** (3): 149-56 [PubMed Abstract](#) | [Publisher Full Text](#)
4. Rostron BL, Chang CM, van Bommel DM, Xia Y, et al.: Nicotine and Toxicant Exposure among U.S. Smokeless Tobacco Users: Results from 1999 to 2012 National Health and Nutrition Examination Survey Data. *Cancer Epidemiol Biomarkers Prev*. 2015; **24** (12): 1829-37 [PubMed Abstract](#) | [Publisher Full Text](#)
5. Food and Drug Administration, C. f. T. P: Draft Guidance: Reporting Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke Under Section 904(a)(3) of the Federal Food, Drug, and Cosmetic Act. 2012. [Reference Source](#)
6. Stanfill SB, Connolly GN, Zhang L, Jia LT, et al.: Global surveillance of oral tobacco products: total nicotine, unionised nicotine and tobacco-specific N-nitrosamines. *Tob Control*. 2011; **20** (3): e2 [PubMed Abstract](#) | [Publisher Full Text](#)
7. Siddiqi K, Shah S, Abbas SM, Vidyasagan A, et al.: Global burden of disease due to smokeless tobacco consumption in adults: analysis of data from 113 countries. *BMC Med*. 2015; **13**: 194 [PubMed Abstract](#) | [Publisher Full Text](#)
8. Boffetta P, Straif K: Use of smokeless tobacco and risk of myocardial infarction and stroke: systematic review with meta-analysis. *BMJ*. 2009; **339**: b3060 [PubMed Abstract](#) | [Publisher Full Text](#)
9. Vidyasagan AL, Siddiqi K, Kanaan M: Use of smokeless tobacco and risk of cardiovascular disease: A systematic review and meta-analysis. *Eur J Prev Cardiol*. **23** (18): 1970-1981 [PubMed Abstract](#) | [Publisher Full Text](#)
10. Rostron BL, Chang JT, Anic GM, Tanwar M, et al.: Smokeless tobacco use and circulatory disease risk: a systematic review and meta-analysis. *Open Heart*. 2018; **5** (2): e000846 [PubMed Abstract](#) | [Publisher Full Text](#)
11. Gupta R, Gupta S, Sharma S, Sinha D, et al.: Risk of Coronary Heart Disease Among Smokeless Tobacco Users: Results of Systematic Review and Meta-Analysis of Global Data. *Nicotine & Tobacco*

Research. 2019; **21** (1): 25-31 [Publisher Full Text](#)

**Are the rationale for, and objectives of, the Systematic Review clearly stated?**

Yes

**Are sufficient details of the methods and analysis provided to allow replication by others?**

Partly

**Is the statistical analysis and its interpretation appropriate?**

Partly

**Are the conclusions drawn adequately supported by the results presented in the review?**

Partly

**Competing Interests:** The reviewers are employees of Altria Client Services LLC.

**Reviewer Expertise:** Tobacco product research, clinical studies, epidemiological evidence, biomarkers, long-term health effects.

**We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above.**

Author Response 02 Sep 2022

**Rachel Murkett**

Dear Dr Sarkar, Dr Anderson, Dr Hannel, Mr Noggle,

Thank you for your thorough review of this study and for your tentative approval. Your clear critique, explanations and suggestions are much appreciated. Please find below a point-by-point commentary. For clarity on the page, I have reduced the key sections of your review into a single sentence summary – these are only intended to identify the sections (not to take away from the full complexity of the points raised).

1. *Comment: Lack of reliable and consistent epidemiological evidence.*

**Response:** We are in complete agreement regarding the issues of missing data, particularly when it comes to comparing combined risk scores that are comprised of data from different analyses. In this study, the combined risk score is used as an indicator of the risk of serious adverse health outcomes due to prolonged nicotine product use based on the best available evidence. As we mention in the limitations of the study, the combined risk score is a very generalised indicator which should not be interpreted as applicable to specific diseases. Part of the rationale for combining these two analyses was to help fill in some of the data gaps in the epidemiological evidence with lifetime cancer risk modelling for the newer products. The lifetime cancer risk is calculated by adjusting unit risk values, which have been determined *in vitro* but validated against epidemiological data collected in humans investigating the probability of cancer incidence in people exposed to the toxin (OEHHA, 2011). For

instance, the unit risk for formaldehyde is validated against a cohort study of industrial workers exposed to formaldehyde (OEHHA, 2011). As such, the lifetime cancer risk analysis is validated against the same type of data as the epidemiological analysis and the comparison of the two datasets is not entirely incoherent. Nevertheless, the suggestion to clarify what data the combined risk scores are composed of in the relative risk hierarchy is appreciated and has been integrated into the update.

2. *Comment: LCR methodology and deviations from Stephens.*

**Response:** The suggested updates regarding further explanation of the methodology for the LCR analysis have been implemented with explanation of the rationale for our choice of toxicants in the methodology section and the OEHHA unit risk values provided in the extended information with the paper.

3. *Comment: Biomarkers of exposure.*

**Response:** Thank you for raising this point about the biomarkers of exposure (BoE) data. There is certainly an argument to be made for including this data as it can account for factors that are lacking in the toxin emissions-based lifetime cancer risk analysis, such as those mentioned: differences in administration routes, absorption, distribution, metabolism, and excretion. We did extract this data and assess it for inclusion in the relative risk hierarchy but decided against this for three main reasons. Firstly, the BoE measurement gives a snapshot of the levels of biomarkers excreted by users of nicotine products at the moment when the sample is taken. BoE measurements are known to show intra-individual variation depending on the elimination half-life of the marker and the intervals between exposure events, meaning that a sample taken one hour after exposure to a nicotine product may give a different biomarker profile compared with a sample taken 4 hours after exposure in the same person, and may not be representative of the peak biomarker level after exposure (Aylward et al., 2014, Smolders et al., 2014, Savitz et al., 2018). In addition, different biomarkers may be at different stages of absorption/metabolism at the time when the sample is taken, so that one metabolite may be at its peak concentration when another could only be at half of its peak concentration. Using the data available, we did not see a good way to correct for this. Secondly, inter-individual variation in levels of consumption, modes of consumption, metabolism, excretion rates, how long after consumption the sample is taken and other confounders also make it difficult to connect the data with peak biomarker levels and get an accurate picture of the individual's exposure over time (Aylward et al., 2014, Smolders et al., 2014, Savitz et al., 2018). While, I recognise that the epidemiological and lifetime cancer risk analyses also have notable limitations, in both cases we are able to link the data obtained with long-term health outcomes quantitatively. In the case of the epidemiological data, sample selection, statistical analysis and logistic regression are used to arrive at odds/hazard ratios that account for common confounders relevant to the context. In the lifetime cancer risk analysis, toxin emissions measured *in vitro* are equated to unit risk values validated against epidemiological data collected in humans. We also adjust the cancer potency according to average daily consumption levels to make the modelled risk representative of lifetime exposure. For biomarker of exposure data, we were not aware of an established method to quantitate the relationship between

the concentration measured and disease incidence or mortality. As such, it did not seem coherent to integrate the BoE data into the relative risk hierarchy with the LCR and epidemiological data. I hope that this explanation clarifies why the biomarker of exposure data was not explored to a greater extent in the paper and why it was not further pursued in this update. While we agree that BoE studies reveal valuable information about toxin exposure in users of different products, it was not suitable for integration with the rest of the dataset included in the relative risk hierarchy.

4. *Comment: Differentiating U.S. smokeless tobacco from other varieties.*

**Response:** This comment is consistent with a key piece of feedback we have received from other parts of the scientific community over the last 2 years when discussing this work. An update of this study was already underway since late 2021, in which the dipping and chewing tobacco categories had been limited to data from U.S. varieties and an additional category was created for smokeless tobacco from the rest of the world, as well as for bidis. This comment has therefore been addressed in the update.

I would like to thank you again for your thorough and constructive critique of this study, and look forward to continuing the discussion.

Best Regards,

Rachel Murkett  
Corresponding author

References:

Aylward LL, Hays SM, Smolders R, Koch HM, Cocker J, Jones K, Warren N, Levy L, Bevan R. Sources of variability in biomarker concentrations. *J Toxicol Environ Health B Crit Rev*. 2014;17(1):45-61. doi: 10.1080/10937404.2013.864250. PMID: 24597909.  
California Office of Environmental Health Hazard Assessment (OEHHA). Technical Support Document for Cancer Potency Factors 2009. Appendix B (updated in 2011). Published online at: [Technical Support Document for Cancer Potency Factors 2009 - OEHHA](#)  
Savitz DA, Wellenius GA. Invited Commentary: Exposure Biomarkers Indicate More Than Just Exposure. *Am J Epidemiol*. 2018 Apr 1;187(4):803-805. doi: 10.1093/aje/kwx333. PMID: 29155925.  
Smolders R, Koch HM, Moos RK, Cocker J, Jones K, Warren N, Levy L, Bevan R, Hays SM, Aylward LL. Inter- and intra-individual variation in urinary biomarker concentrations over a 6-day sampling period. Part 1: metals. *Toxicol Lett*. 2014 Dec 1;231(2):249-60. doi: 10.1016/j.toxlet.2014.08.014. Epub 2014 Aug 13. PMID: 25128590.

**Competing Interests:** No competing interests were disclosed.

Reviewer Report 01 December 2020

<https://doi.org/10.5256/f1000research.29550.r72812>

© 2020 Nutt D. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



### David Nutt

Department of Neuropsychopharmacology and Molecular Imaging, Imperial College London, London, W12 0NN, UK

This study adds to the growing literature that vaping [e-cigarettes] are an important advance in the treatment of tobacco related health harms and in the prevention of these in future. Tobacco use leads to about 7 million premature deaths per year and is estimated to kill over a billion people globally this century. Initial estimates <sup>1,2</sup> suggested that vaping is 25 x less harmful than cigarettes which was incorporated into UK tobacco harm reduction policy <sup>3</sup>. So if the world switched fully to it there would be a saving nearly a billion deaths, then this would be the greatest health impact of any intervention in history. But there is resistance to the concept of harm reduction in tobacco dependence with most governments and medical authorities advocating abstinence – even though this approach has clearly failed – especially in the developing world. A powerful anti-vaping lobby has developed and influenced decision-makers against its use in harm reduction claiming that it could be as harmful as tobacco. They have disseminated misinformation about the harms of vaping that in just a few years have significantly changed smokers perception of its harms and so reduced its use. This paper provides a more recent and more detailed analysis of relative harms that confirms the original 25x less harmful estimate and so should give new impetus to the vaping approach.

### References

1. Nutt DJ, Phillips LD, Balfour D, Curran HV, et al.: Estimating the harms of nicotine-containing products using the MCDA approach. *Eur Addict Res*. 2014; **20** (5): 218-25 [PubMed Abstract](#) | [Publisher Full Text](#)
2. McNeill A, Brose LS, Calder R, Hitchman SC, et al.: E-cigarettes: an evidence update - A report commissioned by Public Health England. 2015. [Reference Source](#)
3. Public Health England: E-cigarettes: a new foundation for evidence-based policy and practice. 2015. [Reference Source](#)

### Are the rationale for, and objectives of, the Systematic Review clearly stated?

Yes

### Are sufficient details of the methods and analysis provided to allow replication by others?

Yes

### Is the statistical analysis and its interpretation appropriate?

I cannot comment. A qualified statistician is required.

### Are the conclusions drawn adequately supported by the results presented in the review?

Yes

**Competing Interests:** No competing interests were disclosed.

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

Author Response 02 Sep 2022

**Rachel Murkett**

Dear Professor Nutt,

Thank you for taking the time to review this study and for your approval of this work. Your feedback on this and future updates are greatly appreciated.

Best regards,

Rachel Murkett  
Corresponding author

**Competing Interests:** No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact [research@f1000.com](mailto:research@f1000.com)

**F1000Research**